<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="systematic-review" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1483186</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2024.1483186</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Systematic Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Global research landscape and emerging trends of non-coding RNAs in prostate cancer: a bibliometric analysis</article-title>
<alt-title alt-title-type="left-running-head">Zhou et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2024.1483186">10.3389/fphar.2024.1483186</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Zhou</surname>
<given-names>Yu-Liang</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2820492/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Yao</surname>
<given-names>Wen-Liang</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Chen</surname>
<given-names>Sheng-Hui</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Peng</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fu</surname>
<given-names>Jing-Wen</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhao</surname>
<given-names>Jia-Qin</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Jia-Yi</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Clinical School of Medicine, Jiangxi University of Chinese Medicine</institution>, <addr-line>Nanchang</addr-line>, <addr-line>Jiangxi</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Andrology</institution>, <institution>Affiliated Reproductive Hospital of Jiangxi University of Chinese Medicine</institution>, <addr-line>Nanchang</addr-line>, <addr-line>Jiangxi</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/36464/overview">Olivier Cuvillier</ext-link>, UPR8241 Laboratoire de Chimie de Coordination (LCC), France</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1206239/overview">Qiong Wang</ext-link>, Southern Medical University, China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1862500/overview">Tian-Bao Huang</ext-link>, Yangzhou University, China</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Sheng-Hui Chen, <email>chenshenhui1965@163.com</email>
</corresp>
<fn fn-type="equal" id="fn001">
<label>
<sup>&#x2020;</sup>
</label>
<p>These authors have contributed equally to this work</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>07</day>
<month>01</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>15</volume>
<elocation-id>1483186</elocation-id>
<history>
<date date-type="received">
<day>19</day>
<month>08</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>13</day>
<month>12</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2025 Zhou, Yao, Chen, Wang, Fu, Zhao and Zhang.</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Zhou, Yao, Chen, Wang, Fu, Zhao and Zhang</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Background</title>
<p>Prostate cancer (PC) is the most frequently diagnosed cancer in men and continues to be a major cause of cancer-related mortality worldwide. In recent years, non-coding RNAs (ncRNAs) have emerged as a significant focus in molecular biology research, playing a pivotal role in the development and progression of PC. This study employed bibliometric analysis to explore the global outputs, research hotspots, and future trends in ncRNA-related PC research over the past 20&#xa0;years.</p>
</sec>
<sec>
<title>Methods</title>
<p>Publications on PC-related ncRNAs from 2004 to 2023 were retrieved from Web of Science Core Collection. The co-operation network of countries, institutions, and authors on this topic was analyzed using CiteSpace (version 6.2. R6). In addition, co-occurrence analysis of keywords and co-citation analysis of references were performed using CiteSpace, and emergent detection was also performed.</p>
</sec>
<sec>
<title>Results</title>
<p>A total of 2,951 articles on PC-related ncRNAs were finally included in this study for analysis. China contributed the largest number of publications, while the United States was the most influential country in this field, with collaborative ties to 26 other countries. Fudan University was identified as the most active institution in this field. Rajvir Dahiya was the most prolific and influential author. Within the co-citation network, clusters labeled &#x201c;EVs,&#x201d; &#x201c;circRNA,&#x201d; and &#x201c;ceRNA&#x201d; represented current research directions. The cluster labeled &#x201c;gene&#x201d; dominated the co-occurrence keywords. &#x201c;circRNA&#x201d; showed the highest burst strength among keywords, with &#x201c;circRNA,&#x201d; &#x201c;EVs&#x201d; and &#x201c;exosome&#x201d; maintaining sustained burst strength, suggesting these are the emerging research frontiers in this field.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>Investigating ncRNAs as pivotal research subjects in PC is essential for addressing the public health impact of the disease and advancing innovative diagnostic and targeted therapeutic strategies. This study provides a comprehensive bibliometric analysis of research related to PC-associated ncRNAs, delivering a scientific perspective and identifying potential research directions for scholars in this field.</p>
</sec>
</abstract>
<kwd-group>
<kwd>non-coding RNA</kwd>
<kwd>prostate cancer</kwd>
<kwd>bibliometric analysis</kwd>
<kwd>extracellular vesicle</kwd>
<kwd>circular RNA</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Pharmacology of Anti-Cancer Drugs</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1">
<title>1 Introduction</title>
<p>Prostate cancer (PC) is one of the most common malignancies threatening men&#x2019;s health (<xref ref-type="bibr" rid="B55">Litwin and Tan, 2017</xref>). According to GLOBOCAN cancer statistics, PC had an estimated 1.5 million new cases and 397,000 deaths globally in 2022, making it the second most common cancer and the fifth leading cause of cancer-related mortality among men (<xref ref-type="bibr" rid="B7">Bray et al., 2024</xref>). As an age-related malignancy of the male genitourinary system, PC has a higher incidence in elderly populations and continues to rise with the increasing aging of the population (<xref ref-type="bibr" rid="B82">Siegel et al., 2023</xref>). Family history, race, and genetic syndromes are established risk factors for PC, while smoking and obesity have a suspected role in modulating PC-specific mortality (<xref ref-type="bibr" rid="B27">Gandaglia et al., 2021</xref>). In its early stages, PC is asymptomatic, with early detection primarily achieved through blood tests for prostate-specific antigen (PSA) and confirmed via tissue biopsy (<xref ref-type="bibr" rid="B98">Van Poppel et al., 2022</xref>). Although radiation therapy and radical prostatectomy are effective treatments for localized PC, they may increase the risk of treatment-related complications, including incontinence and erectile dysfunction from surgery, and gastrointestinal and erectile dysfunction from radiation therapy (<xref ref-type="bibr" rid="B68">Pinsky and Parnes, 2023</xref>). Androgen deprivation therapy (ADT) is the standard treatment for recurrent or metastatic PC patients, encompassing both surgical and pharmacological castration, with the latter being more commonly employed (<xref ref-type="bibr" rid="B22">Feldman and Feldman, 2001</xref>). The goal of ADT is to lower serum testosterone levels in PC patients and maintain this suppression to induce cancer cell death and achieve transient clinical remission (<xref ref-type="bibr" rid="B77">Schr&#xf6;der et al., 2012</xref>). Nevertheless, the vast majority of PC patients subjected to ADT will ultimately develop castration-resistant PC (CRPC), which is a leading cause of mortality among these patients (<xref ref-type="bibr" rid="B9">Cai et al., 2023</xref>).</p>
<p>For decades, the functional focus of PC research has primarily been on protein-coding genes. However, these genes constitute only about 2%&#x2013;3% of the human genome, while the diverse and ubiquitous non-coding RNAs (ncRNAs) originate from the remaining nucleotides (<xref ref-type="bibr" rid="B73">Rinn and Guttman, 2014</xref>). With the advent of high-throughput sequencing technologies, most of the non-coding genome has been characterized as functional transcripts, playing crucial roles in various biological processes and pathological states (<xref ref-type="bibr" rid="B84">Slack and Chinnaiyan, 2019</xref>). ncRNAs are localized in both the nucleus and cytoplasm and can also be found within extracellular vesicles (EVs), such as exosomes, or other microvesicles in bodily fluids. Based on their length, ncRNAs can be broadly categorized into two main families: small ncRNAs, which are shorter than 200 nucleotides and include microRNAs, transfer RNA-derived small RNAs, and Piwi-interacting RNAs, and long ncRNAs (lncRNAs), which exceed 200 nucleotides and encompass pseudogenes, chimeric RNAs, and circular RNAs (circRNAs) (<xref ref-type="bibr" rid="B8">Brosnan and Voinnet, 2009</xref>; <xref ref-type="bibr" rid="B79">Shi et al., 2021</xref>). As competing endogenous RNAs (ceRNAs), ncRNAs interact with protein-coding messenger RNAs (mRNAs) in complex ways, offering new insights into the gene regulatory networks of humans. Notably, recent studies have demonstrated that certain ncRNAs, initially considered incapable of protein-coding, contribute critically to disease development and progression through the production of derived peptides or proteins (<xref ref-type="bibr" rid="B102">Wang et al., 2019</xref>; <xref ref-type="bibr" rid="B117">Yi et al., 2024</xref>). ncRNA therapies have progressed relatively slowly on a global scale, with most ncRNA-related drugs still in the early phases of human clinical trials. For example, a 13-mer locked nucleic acid (LNA) inhibitor of miR-221, known as LNA-i-miR-221, demonstrated promising anti-tumor activity and safety in a Phase I clinical study (<xref ref-type="bibr" rid="B93">Tassone et al., 2023</xref>). The miR-122 inhibitor miravirsen resulted in a dose-dependent reduction of hepatitis C virus RNA levels in a Phase II clinical trial (<xref ref-type="bibr" rid="B42">Janssen et al., 2013</xref>). Similarly, CDR132L, a miR-132 inhibitor, has demonstrated effectiveness in improving cardiac function in patients with heart failure (<xref ref-type="bibr" rid="B94">T&#xe4;ubel et al., 2021</xref>). Additionally, remlarsen (miR-29b mimic) was found to inhibit collagen expression and the development of fibroproliferation in incisional skin wounds among healthy volunteers (<xref ref-type="bibr" rid="B25">Gallant-Behm et al., 2019</xref>). Recent studies have extensively reported abnormal expression of ncRNAs as a significant feature of PC, identifying them as key players in the onset and progression of the disease (<xref ref-type="bibr" rid="B70">Ramalho-Carvalho et al., 2016</xref>; <xref ref-type="bibr" rid="B63">Mugoni et al., 2022</xref>). Research into the biology of ncRNAs not only reveals their potential roles in PC pathology but also provides a theoretical foundation for specific diagnostic, therapeutic, and preventive strategies targeting ncRNAs in the human genome.</p>
<p>Bibliometrics offers an objective approach for objectively reflecting the knowledge structure and emerging trends in a particular field through quantitative analysis of published scientific literature (<xref ref-type="bibr" rid="B65">Nicolaisen, 2010</xref>). CiteSpace, as a tool for visualizing scientific knowledge, aids researchers in examining contributions from authors, countries, and institutions, identifying rapidly evolving topics, and forecasting future research directions (<xref ref-type="bibr" rid="B13">Chen, 2004</xref>; <xref ref-type="bibr" rid="B90">Synnestvedt et al., 2005</xref>). For instance, <xref ref-type="bibr" rid="B125">Zhong et al. (2022)</xref> utilized bibliometric analysis to evaluate global scientific output on immunotherapy for PC from 1999 to 2021, summarizing future research trends. Similarly, <xref ref-type="bibr" rid="B16">Chen et al. (2022)</xref> investigated the research status, hotspots, and trends in bone metastases of PC through bibliometric analysis. Despite the rapid advancement of research on ncRNAs in recent years, the impact of these studies on the PC field has not yet been fully assessed. Therefore, this study aimed to employ bibliometric analysis and knowledge domain mapping to evaluate the publications on ncRNAs in PC published over the past 20&#xa0;years in the Web of Science Core Collection (WoSCC), with the goal of identifying the knowledge domain and emerging trends in this field.</p>
</sec>
<sec sec-type="methods" id="s2">
<title>2 Methods</title>
<sec id="s2-1">
<title>2.1 Data collection</title>
<p>The Science Citation Index-Expanded (SCI-Expanded) of WoSCC was searched for publications related to ncRNAs in PC. The retrieval strategy used in this study was &#x201c;TS &#x3d; [(&#x201c;miRNA&#x2a;&#x201d; OR &#x201c;microRNA&#x2a;&#x201d; OR &#x201c;miR-&#x2a;&#x201d; OR &#x201c;lncRNA&#x2a;&#x201d; OR &#x201c;long noncoding RNA&#x2a;&#x201d; OR &#x201c;long non-coding RNA&#x2a;&#x201d; OR &#x201c;circRNA&#x2a;&#x201d; OR &#x201c;circular RNA&#x2a;&#x201d; OR &#x201c;circ_&#x2a;&#x201d; OR &#x201c;non-coding RNA&#x2a;&#x201d; OR &#x201c;noncoding RNA&#x2a;&#x201d;) AND (&#x201c;prostate cancer&#x201d; OR &#x201c;prostate neoplasm&#x201d;)].&#x201d; The search time span was set to between 1 January 2004 and 31 December 2023. In the first stage of screening, the type of publication was restricted to Article and the language was limited to English. In the second stage, irrelevant publications were excluded based on the title, keyword, abstract, and full text. The full records and cited references of eligible articles were exported from SCI-Expanded in plain text format. The flow chart of research steps of this study is shown in <xref ref-type="fig" rid="F1">Figure 1</xref>.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Flowchart of the selection process.</p>
</caption>
<graphic xlink:href="fphar-15-1483186-g001.tif"/>
</fig>
</sec>
<sec id="s2-2">
<title>2.2 Bibliometric analysis</title>
<p>All valid data were imported into Origin (version 2021) or CiteSpace (version 6.2. R6) for analysis and visualization. Origin was used to conduct statistical analysis on the annual number of publications and their citations, and to visualize the collaborations between different countries. CiteSpace was performed for co-operation analysis of countries, institutions, and authors. In addition, we used CiteSpace to draw a dual-map overlay of journals to investigate the evolutionary relationship between knowledge topics in directly citing journals and cited journals. In keyword analysis, we merged keywords with the same meaning to get a better perspective. The co-occurrence analysis of keywords and the co-citation analysis of references were performed by CiteSpace. Moreover, burst detection in CiteSpace was used to detect sudden surges in references and keywords at a certain time.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>3 Results</title>
<sec id="s3-1">
<title>3.1 Publication outputs and trends</title>
<p>A total of 2,951 articles on ncRNAs in PC were screened from 7,630 records retrieved from WoSCC. According to the number of citations, the total citations of the top 10 most cited papers accounted for 43.87% of all papers (<xref ref-type="sec" rid="s11">Supplementary Table S1</xref>). The most cited article was titled &#x201c;<italic>c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism,</italic>&#x201d; which had 1,641 citations in <italic>Nature</italic>. The article published in <italic>Cell</italic> titled &#x201c;<italic>The Landscape of Circular RNA in Cancer</italic>&#x201d; had the highest annual citation frequency. The distribution of publications and their citations is presented in <xref ref-type="fig" rid="F2">Figure 2</xref>. From 2004 to 2023, the cumulative number of global publications showed a consistent upward trend. Specifically, the evolution of PC-related ncRNA research consisted of threee stages. The field was in its early stages from 2004 to 2008, when fewer than 20 papers were published each year. The second stage was from 2009 to 2021, with a rapid increase in the number of annual publications. As the third stage from 2022 to 2023, the number of annual publications was in a steady growth, and the cumulative number of publications in 2023 was 113.5 times that of 2008. The cumulative number of citations for all articles in 2023 was 21,846, with an average of 7 citations per article. These results indicate that ncRNA research is an active field in PC and has received extensive attention from scholars.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>The distribution of publications <bold>(A)</bold> and their citations <bold>(B)</bold> from 2004 to 2023. The data were extracted using CiteSpace, and the figure was created with Origin.</p>
</caption>
<graphic xlink:href="fphar-15-1483186-g002.tif"/>
</fig>
</sec>
<sec id="s3-2">
<title>3.2 Analysis of countries/regions and institutions</title>
<p>Analyzing the research output of countries/regions and institutions provides insights into the global distribution and trends within a specific field, enabling the identification of influential countries/regions and institutions. A total of 78 countries/regions were involved in the publications of ncRNAs in PC. Among them, China (1,665), the United States (699), Germany (131), Canada (120), and Italy (112) were the top five productive countries/regions in terms of the number of publications (<xref ref-type="table" rid="T1">Table 1</xref>). The H-index is a hybrid quantitative metric used to measure academic impact. The United States (119) has the highest H-index, indicating its leading academic influence in PC-related ncRNA research, followed by China (88), Canada (47), Japan (46), and Italy (43). Centrality helps identify key roles in information flow and knowledge dissemination within a network. The United (0.56) States exhibited the highest centrality, followed by China (0.27), the United Kingdom (0.2), Canada (0.11), and Germany (0.1). As depicted in <xref ref-type="fig" rid="F3">Figure 3A</xref>, the United States collaborated with 26 other countries, notably including China, Canada, and the United Kingdom, which underscores its significant role as a central hub in international collaborations.</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Top 10 productive countries/regions of ncRNA research in PC from 2004 to 2023.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">Rank</th>
<th align="center">Country</th>
<th align="center">Counts</th>
<th align="center">Percentage</th>
<th align="center">H-index</th>
<th align="center">Centrality</th>
<th align="center">Total citations</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="center">1</td>
<td align="center">China</td>
<td align="center">1,665</td>
<td align="center">56.42</td>
<td align="center">88</td>
<td align="center">0.27</td>
<td align="center">47,992</td>
</tr>
<tr>
<td align="center">2</td>
<td align="center">United States</td>
<td align="center">699</td>
<td align="center">23.69</td>
<td align="center">119</td>
<td align="center">0.56</td>
<td align="center">53,405</td>
</tr>
<tr>
<td align="center">3</td>
<td align="center">Germany</td>
<td align="center">131</td>
<td align="center">4.44</td>
<td align="center">42</td>
<td align="center">0.1</td>
<td align="center">6,767</td>
</tr>
<tr>
<td align="center">4</td>
<td align="center">Canada</td>
<td align="center">120</td>
<td align="center">4.07</td>
<td align="center">47</td>
<td align="center">0.11</td>
<td align="center">7,106</td>
</tr>
<tr>
<td align="center">5</td>
<td align="center">Italy</td>
<td align="center">112</td>
<td align="center">3.80</td>
<td align="center">43</td>
<td align="center">0.07</td>
<td align="center">6,487</td>
</tr>
<tr>
<td align="center">6</td>
<td align="center">Japan</td>
<td align="center">100</td>
<td align="center">3.39</td>
<td align="center">46</td>
<td align="center">0.02</td>
<td align="center">8,339</td>
</tr>
<tr>
<td align="center">7</td>
<td align="center">United Kingdom</td>
<td align="center">93</td>
<td align="center">3.15</td>
<td align="center">34</td>
<td align="center">0.2</td>
<td align="center">5,276</td>
</tr>
<tr>
<td align="center">8</td>
<td align="center">Australia</td>
<td align="center">56</td>
<td align="center">1.90</td>
<td align="center">31</td>
<td align="center">0.03</td>
<td align="center">2,981</td>
</tr>
<tr>
<td align="center">9</td>
<td align="center">Brazil</td>
<td align="center">52</td>
<td align="center">1.76</td>
<td align="center">25</td>
<td align="center">0.05</td>
<td align="center">1,920</td>
</tr>
<tr>
<td align="center">10</td>
<td align="center">Iran</td>
<td align="center">52</td>
<td align="center">1.76</td>
<td align="center">16</td>
<td align="center">0.09</td>
<td align="center">882</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>The data were extracted using CiteSpace.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Collaboration network of countries/regions and institutions of ncRNA research in PC from 2004 to 2023. <bold>(A)</bold> The cooperation string diagram between top 30 countries/regions. <bold>(B)</bold> The network visualization map of different institutions. Each node represents an institution, and the size of the node corresponds to the frequency of publications produced by that institution. Each link between two nodes indicates a collaborative relationship between the respective institutions. Nodes with purple rings denote higher centrality, signifying their prominent role in the collaboration network. The data were extracted using CiteSpace. Panel <bold>(A)</bold> was created using Origin, while Panel <bold>(B)</bold> was generated with CiteSpace.</p>
</caption>
<graphic xlink:href="fphar-15-1483186-g003.tif"/>
</fig>
<p>Based on the number of publications, <xref ref-type="table" rid="T2">Table 2</xref> presents the top 10 institutions of ncRNA research in PC, with 9 of them located in China. Fudan University (98) had the highest number of publications, followed by Shanghai Jiao Tong University (96), Nanjing Medical University (91), and Sun Yat-sen University (91). Furthermore, the H-index of Sun Yat-sen University (36) and Harvard University (36) was the highest, followed by Fudan University (34) and Shanghai Jiao Tong University (33). Visualized with CiteSpace, we mapped an institutional collaboration network consisting of 102 nodes and 112 linkages (<xref ref-type="fig" rid="F3">Figure 3B</xref>). Southern Medical University (0.41) had the highest centrality, followed by Guangzhou Medical University (0.36) and Nanjing Medical University (0.29). As the institution with the most publications, Fudan University primarily had close collaborations with Naval Medical University, Tongji University, and Chinese Academy of Sciences.</p>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>Top 10 productive institutions of ncRNA research in PC from 2004 to 2023.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">Rank</th>
<th align="center">Institution</th>
<th align="center">Country</th>
<th align="center">Counts</th>
<th align="center">H-index</th>
<th align="center">Centrality</th>
<th align="center">Total citations</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="center">1</td>
<td align="center">Fudan University</td>
<td align="center">China</td>
<td align="center">98</td>
<td align="center">34</td>
<td align="center">0.24</td>
<td align="center">3,472</td>
</tr>
<tr>
<td align="center">2</td>
<td align="center">Shanghai Jiao Tong University</td>
<td align="center">China</td>
<td align="center">96</td>
<td align="center">33</td>
<td align="center">0.14</td>
<td align="center">3,297</td>
</tr>
<tr>
<td align="center">3</td>
<td align="center">Nanjing Medical University</td>
<td align="center">China</td>
<td align="center">91</td>
<td align="center">30</td>
<td align="center">0.29</td>
<td align="center">3,096</td>
</tr>
<tr>
<td align="center">4</td>
<td align="center">Sun Yat-sen University</td>
<td align="center">China</td>
<td align="center">91</td>
<td align="center">36</td>
<td align="center">0.01</td>
<td align="center">3,700</td>
</tr>
<tr>
<td align="center">5</td>
<td align="center">Southern Medical University</td>
<td align="center">China</td>
<td align="center">69</td>
<td align="center">27</td>
<td align="center">0.41</td>
<td align="center">1,971</td>
</tr>
<tr>
<td align="center">6</td>
<td align="center">Harvard University</td>
<td align="center">United States</td>
<td align="center">63</td>
<td align="center">36</td>
<td align="center">0.15</td>
<td align="center">4,674</td>
</tr>
<tr>
<td align="center">7</td>
<td align="center">Guangzhou Medical University</td>
<td align="center">China</td>
<td align="center">62</td>
<td align="center">31</td>
<td align="center">0.36</td>
<td align="center">2,379</td>
</tr>
<tr>
<td align="center">8</td>
<td align="center">Tongji University</td>
<td align="center">China</td>
<td align="center">57</td>
<td align="center">26</td>
<td align="center">0.15</td>
<td align="center">2,303</td>
</tr>
<tr>
<td align="center">9</td>
<td align="center">University of Toronto</td>
<td align="center">Canada</td>
<td align="center">55</td>
<td align="center">30</td>
<td align="center">0.09</td>
<td align="center">2,834</td>
</tr>
<tr>
<td align="center">10</td>
<td align="center">Shandong University</td>
<td align="center">China</td>
<td align="center">55</td>
<td align="center">24</td>
<td align="center">0.03</td>
<td align="center">1,640</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>The data were extracted using CiteSpace.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s3-3">
<title>3.3 Analysis of authors</title>
<p>Author analysis facilitates the identification of pivotal contributors within a field and offers insights to guide academic exchanges and project collaborations. The top 10 active authors are listed in <xref ref-type="table" rid="T3">Table 3</xref>. Rajvir Dahiya contributed the most research with 34 publications, followed by Sharanjot Saini (29) and Yuichiro Tanaka (29). According to authors&#x2019; H-index, Rajvir Dahiya (23) ranked first, followed by Naohiko Seki (22), Sharanjot Saini (20), Yuichiro Tanaka (20), Shahana Majid (20), and Arul M Chinnaiyan (20). Rajvir Dahiya made significant contributions, with his research emphasizing the regulatory roles of miRNAs in the proliferation and metastasis of PC (<xref ref-type="bibr" rid="B66">Noonan et al., 2009</xref>; <xref ref-type="bibr" rid="B74">Saini et al., 2011</xref>). Co-cited authors are those cited together in one or more publications, used to identify key researchers in a particular academic field. <xref ref-type="sec" rid="s11">Supplementary Table S2</xref> shows that Rebecca L Siegel (978) had the most co-citations, followed by David P Bartel (451) and Ahmedin Jemal (394). These scholars have established the groundwork for research on ncRNAs in PC.</p>
<table-wrap id="T3" position="float">
<label>TABLE 3</label>
<caption>
<p>Top 10 active authors of ncRNA research in PC from 2004 to 2023.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">Rank</th>
<th align="center">Author</th>
<th align="center">Counts</th>
<th align="center">H-index</th>
<th align="center">Total citations</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="center">1</td>
<td align="center">Rajvir Dahiya</td>
<td align="center">34</td>
<td align="center">23</td>
<td align="center">2,982</td>
</tr>
<tr>
<td align="center">2</td>
<td align="center">Sharanjot Saini</td>
<td align="center">29</td>
<td align="center">20</td>
<td align="center">2,267</td>
</tr>
<tr>
<td align="center">3</td>
<td align="center">Yuichiro Tanaka</td>
<td align="center">29</td>
<td align="center">20</td>
<td align="center">2,559</td>
</tr>
<tr>
<td align="center">4</td>
<td align="center">Shahana Majid</td>
<td align="center">28</td>
<td align="center">20</td>
<td align="center">2,355</td>
</tr>
<tr>
<td align="center">5</td>
<td align="center">Varahram Shahryari</td>
<td align="center">24</td>
<td align="center">18</td>
<td align="center">1,931</td>
</tr>
<tr>
<td align="center">6</td>
<td align="center">Soichiro Yamamura</td>
<td align="center">24</td>
<td align="center">18</td>
<td align="center">1,976</td>
</tr>
<tr>
<td align="center">7</td>
<td align="center">Tapio Visakorpi</td>
<td align="center">24</td>
<td align="center">19</td>
<td align="center">2,898</td>
</tr>
<tr>
<td align="center">8</td>
<td align="center">Naohiko Seki</td>
<td align="center">24</td>
<td align="center">22</td>
<td align="center">1,782</td>
</tr>
<tr>
<td align="center">9</td>
<td align="center">Arul M Chinnaiyan</td>
<td align="center">22</td>
<td align="center">20</td>
<td align="center">5,096</td>
</tr>
<tr>
<td align="center">10</td>
<td align="center">Ming Chen</td>
<td align="center">22</td>
<td align="center">19</td>
<td align="center">929</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>The data were extracted using CiteSpace.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s3-4">
<title>3.4 Analysis of journals</title>
<p>Journal analysis provides researchers with prioritized options for submitting their work and accessing articles within a specific field. A total of 556 academic journals included articles on PC-related ncRNAs. The top 10 journals included 658 papers in the field, accounting for 22.30% of all publications (<xref ref-type="table" rid="T4">Table 4</xref>). <italic>PLoS One</italic> (102) was the most published journal, followed by <italic>Prostate</italic> (97), <italic>Oncotarget</italic> (95), <italic>Oncogene</italic> (61), and <italic>Scientific Reports</italic> (60). <italic>Cancer Research</italic> (6,656), <italic>PLoS One</italic> (6,567), and <italic>Oncogene</italic> (5,663) were the top three most frequently cited journals.</p>
<table-wrap id="T4" position="float">
<label>TABLE 4</label>
<caption>
<p>Top 10 active journals of ncRNA research in PC from 2004 to 2023.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">Rank</th>
<th align="center">Journal</th>
<th align="center">Counts</th>
<th align="center">H-index</th>
<th align="center">Total citations</th>
<th align="center">IF (2023)</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="center">1</td>
<td align="center">
<italic>PLoS One</italic>
</td>
<td align="center">102</td>
<td align="center">49</td>
<td align="center">6,567</td>
<td align="center">2.9</td>
</tr>
<tr>
<td align="center">2</td>
<td align="center">
<italic>Prostate</italic>
</td>
<td align="center">97</td>
<td align="center">42</td>
<td align="center">5,343</td>
<td align="center">2.6</td>
</tr>
<tr>
<td align="center">3</td>
<td align="center">
<italic>Oncotarget</italic>
</td>
<td align="center">95</td>
<td align="center">49</td>
<td align="center">5,408</td>
<td align="center">NA</td>
</tr>
<tr>
<td align="center">4</td>
<td align="center">
<italic>Oncogene</italic>
</td>
<td align="center">61</td>
<td align="center">40</td>
<td align="center">5,663</td>
<td align="center">6.9</td>
</tr>
<tr>
<td align="center">5</td>
<td align="center">
<italic>Scientific Reports</italic>
</td>
<td align="center">60</td>
<td align="center">26</td>
<td align="center">1,627</td>
<td align="center">3.8</td>
</tr>
<tr>
<td align="center">6</td>
<td align="center">
<italic>Oncology Letters</italic>
</td>
<td align="center">54</td>
<td align="center">20</td>
<td align="center">941</td>
<td align="center">2.5</td>
</tr>
<tr>
<td align="center">7</td>
<td align="center">
<italic>Cancers</italic>
</td>
<td align="center">48</td>
<td align="center">13</td>
<td align="center">521</td>
<td align="center">4.5</td>
</tr>
<tr>
<td align="center">8</td>
<td align="center">
<italic>European Review for Medical and Pharmacological Sciences</italic>
</td>
<td align="center">48</td>
<td align="center">18</td>
<td align="center">869</td>
<td align="center">NA</td>
</tr>
<tr>
<td align="center">9</td>
<td align="center">
<italic>Cancer Research</italic>
</td>
<td align="center">47</td>
<td align="center">41</td>
<td align="center">6,656</td>
<td align="center">12.5</td>
</tr>
<tr>
<td align="center">10</td>
<td align="center">
<italic>International Journal of Molecular Sciences</italic>
</td>
<td align="center">46</td>
<td align="center">15</td>
<td align="center">680</td>
<td align="center">4.9</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>The data were extracted using CiteSpace.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The top 20 active co-cited journals are presented in <xref ref-type="sec" rid="s11">Supplementary Table S3</xref>. Among them, <italic>Cancer Research</italic> (5,615) had the most co-citations, followed by <italic>Oncogene</italic> (3,325), <italic>PLoS One</italic> (3,190), <italic>Cell</italic> (3,034), and <italic>Proceedings of the National Academy of Sciences</italic> (2,720). In addition, to investigate the evolutionary relationship between knowledge topics in directly citing journals and cited journals, we used CiteSpace to draw a dual-map overlay of journals, in which the topics of directly citing journals are distributed on the left and the topics of cited journals are represented on the right. The analysis presented in <xref ref-type="sec" rid="s11">Supplementary Figure S1</xref> revealed a prominent citation pathway, indicating that research published in Molecular/Biology/Genetics journals was predominantly referenced by studies from Molecular/Biology/Immunology journals.</p>
</sec>
<sec id="s3-5">
<title>3.5 Co-citation analysis of references</title>
<p>To track the knowledge structure and research trends in the field of PC-related ncRNAs, we conducted a co-citation analysis of the references from 2,951 articles with CiteSpace. <xref ref-type="sec" rid="s11">Supplementary Table S4</xref> shows the top 10 frequently co-cited references. Among them, &#x201c;(<xref ref-type="bibr" rid="B81">Siegel et al., 2017</xref>)&#x201d; was the most co-cited reference, with 406 citations. Subsequently, the clustering analysis of CiteSpace was performed to construct a map of co-cited references, which consisted of 842 filtered nodes, 1917 connections, and 10 clusters (<xref ref-type="fig" rid="F4">Figure 4</xref>). The modularity Q score was 0.7094 (&#x3e;0.3), and the mean silhouette S was 0.867 (&#x3e;0.7), demonstrating both a significant clustering structure and a highly homogeneous clustering network. <xref ref-type="sec" rid="s11">Supplementary Figure S2</xref> displays the timeline view of co-cited references, highlighting the evolution of each cluster over time. The largest cluster was &#x201c;EVs&#x201d; (cluster &#x23;0), followed by &#x201c;PC&#x201d; (cluster &#x23;1) and &#x201c;circRNA&#x201d; (cluster &#x23;2). According to the results of cluster analysis, &#x201c;microarray&#x201d; (cluster &#x23;7), &#x201c;PC&#x201d; (cluster &#x23;1), and &#x201c;HRPC&#x201d; (cluster &#x23;8) represented the early knowledge base in the field of PC-related ncRNAs in the past 20&#xa0;years, while &#x201c;EVs&#x201d; (cluster &#x23;0), &#x201c;circRNA&#x201d; (cluster &#x23;2), and &#x201c;ceRNA&#x201d; (cluster &#x23;4) reflected the current research direction.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>The network map of co-cited references related to ncRNA research in PC from 2004 to 2023. Each node represents a filtered co-cited reference, with the size of the node indicating its co-citation frequency. Each link between two nodes indicates a co-citation relationship between the respective references. Both the data and figures were generated using CiteSpace.</p>
</caption>
<graphic xlink:href="fphar-15-1483186-g004.tif"/>
</fig>
<p>Furthermore, through the burst detection function of CiteSpace, we explored the top 15 co-cited references with strong citation bursts (<xref ref-type="table" rid="T5">Table 5</xref>). The paper that first exhibited strong citation burst over the past 20&#xa0;years was &#x201c;<italic>A microRNA expression signature of human solid tumors defines cancer gene targets,</italic>&#x201d; authored by Stefano Volinia and published in 2006. The paper titled &#x201c;<italic>microRNA expression in human prostate cancer</italic>&#x201d; published in 2008 received the strongest citation burst (46.12), followed by &#x201c;Kati P Porkka, 2007&#x201d; (42.48), and &#x201c;Stefan Ambs, 2008&#x201d; (38.65). These papers constitute significant events in the current knowledge base of PC-related ncRNA research.</p>
<table-wrap id="T5" position="float">
<label>TABLE 5</label>
<caption>
<p>Top 15 co-cited references with strong citation bursts related to ncRNA research in PC from 2004 to 2023.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">Rank</th>
<th align="center">Co-cited reference</th>
<th align="center">Author</th>
<th align="center">Journal</th>
<th align="center">Year</th>
<th align="center">Burst strength</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="center">1</td>
<td align="center">
<italic>A microRNA expression signature of human solid tumors defines cancer gene targets</italic>
</td>
<td align="center">Stefano Volinia</td>
<td align="center">
<italic>Proc Natl Acad Sci U S A</italic>
</td>
<td align="center">2006</td>
<td align="center">33.29</td>
</tr>
<tr>
<td align="center">2</td>
<td align="center">
<italic>MicroRNA expression profiling in prostate cancer</italic>
</td>
<td align="center">Kati P Porkka</td>
<td align="center">
<italic>Cancer Res</italic>
</td>
<td align="center">2007</td>
<td align="center">42.48</td>
</tr>
<tr>
<td align="center">3</td>
<td align="center">
<italic>Widespread deregulation of microRNA expression in human prostate cancer</italic>
</td>
<td align="center">M Ozen</td>
<td align="center">
<italic>Oncogene</italic>
</td>
<td align="center">2008</td>
<td align="center">46.12</td>
</tr>
<tr>
<td align="center">4</td>
<td align="center">
<italic>Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer</italic>
</td>
<td align="center">Stefan Ambs</td>
<td align="center">
<italic>Cancer Res</italic>
</td>
<td align="center">2008</td>
<td align="center">38.65</td>
</tr>
<tr>
<td align="center">5</td>
<td align="center">
<italic>Circulating microRNAs as stable blood-based markers for cancer detection</italic>
</td>
<td align="center">Patrick S Mitchell</td>
<td align="center">
<italic>Proc Natl Acad Sci U S A</italic>
</td>
<td align="center">2008</td>
<td align="center">24.27</td>
</tr>
<tr>
<td align="center">6</td>
<td align="center">
<italic>MicroRNA profile analysis of human prostate cancers</italic>
</td>
<td align="center">A W Tong</td>
<td align="center">
<italic>Cancer Gene Ther</italic>
</td>
<td align="center">2009</td>
<td align="center">21.29</td>
</tr>
<tr>
<td align="center">7</td>
<td align="center">
<italic>miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth</italic>
</td>
<td align="center">Judit Ribas</td>
<td align="center">
<italic>Cancer Res</italic>
</td>
<td align="center">2009</td>
<td align="center">19.19</td>
</tr>
<tr>
<td align="center">8</td>
<td align="center">
<italic>Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma</italic>
</td>
<td align="center">Annika Schaefer</td>
<td align="center">
<italic>Int J Cancer</italic>
</td>
<td align="center">2010</td>
<td align="center">38.55</td>
</tr>
<tr>
<td align="center">9</td>
<td align="center">
<italic>Integrative genomic profiling of human prostate cancer</italic>
</td>
<td align="center">Barry S Taylor</td>
<td align="center">
<italic>Cancer Cell</italic>
</td>
<td align="center">2010</td>
<td align="center">31.91</td>
</tr>
<tr>
<td align="center">10</td>
<td align="center">
<italic>Cancer statistics, 2013</italic>
</td>
<td align="center">Rebecca L. Siegel</td>
<td align="center">
<italic>CA Cancer J Clin</italic>
</td>
<td align="center">2013</td>
<td align="center">24.98</td>
</tr>
<tr>
<td align="center">11</td>
<td align="center">
<italic>Cancer statistics, 2014</italic>
</td>
<td align="center">Rebecca L. Siegel</td>
<td align="center">
<italic>CA Cancer J Clin</italic>
</td>
<td align="center">2014</td>
<td align="center">32.53</td>
</tr>
<tr>
<td align="center">12</td>
<td align="center">
<italic>Cancer Statistics, 2017</italic>
</td>
<td align="center">Rebecca L. Siegel</td>
<td align="center">
<italic>CA Cancer J Clin</italic>
</td>
<td align="center">2017</td>
<td align="center">31.19</td>
</tr>
<tr>
<td align="center">13</td>
<td align="center">
<italic>The Molecular Taxonomy of Primary Prostate Cancer</italic>
</td>
<td align="center">Cancer Genome Atlas Research Network</td>
<td align="center">
<italic>Cell</italic>
</td>
<td align="center">2015</td>
<td align="center">26.97</td>
</tr>
<tr>
<td align="center">14</td>
<td align="center">
<italic>Cancer statistics in China, 2015</italic>
</td>
<td align="center">Wanqing Chen</td>
<td align="center">
<italic>CA Cancer J Clin</italic>
</td>
<td align="center">2016</td>
<td align="center">21.43</td>
</tr>
<tr>
<td align="center">15</td>
<td align="center">
<italic>Prostate cancer</italic>
</td>
<td align="center">Gerhardt Attard</td>
<td align="center">
<italic>Lancet</italic>
</td>
<td align="center">2016</td>
<td align="center">20.94</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>The data were extracted using CiteSpace.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s3-6">
<title>3.6 Analysis of keywords</title>
<p>Identifying the high-frequency keywords in research on PC-associated ncRNAs facilitates the rapid recognition of the hot topics of interest within the academic community. <xref ref-type="sec" rid="s11">Supplementary Table S5</xref> lists the top 50 most frequent keywords, with the 15 highest-ranking ones being &#x201c;PC&#x201d; (1938), &#x201c;expression&#x201d; (1,258), &#x201c;miRNA&#x201d; (809), &#x201c;proliferation&#x201d; (688), &#x201c;metastasis&#x201d; (632), &#x201c;progression&#x201d; (521), &#x201c;growth&#x201d; (492), &#x201c;cancer cell&#x201d; (490), &#x201c;invasion&#x201d; (447), &#x201c;gene&#x201d; (360), &#x201c;biomarker&#x201d; (352), &#x201c;lncRNA&#x201d; (329), &#x201c;androgen receptors&#x201d; (284), &#x201c;cancer&#x201d; (268), and &#x201c;apoptosis&#x201d; (265). Among these high-frequency keywords, those pertaining to ncRNAs include &#x201c;miRNA&#x201d; (809), &#x201c;lncRNA&#x201d; (329), and &#x201c;circRNA&#x201d; (82). The co-occurrence analysis of keywords helps elucidate the relationships between different knowledge points in PC-associated ncRNA research, thereby contributing to the construction of a knowledge map for the field. To obtain a better network visualization of the keyword co-occurrence, we merged similar keywords from 2,951 articles, resulting in a co-occurrence map with 129 filtered nodes, 137 connections, and 11 clusters (<xref ref-type="fig" rid="F5">Figure 5A</xref>). The modularity Q score was 0.8081, and the mean silhouette S reached 0.9215, indicating the highly convincing keyword network. In addition, we presented a visualization of the evolution of keywords in different clusters over time in the form of a timeline view (<xref ref-type="sec" rid="s11">Supplementary Figure S3</xref>). &#x201c;gene&#x201d; (cluster &#x23;0) was the largest cluster, encompassing keywords such as &#x201c;miRNA,&#x201d; &#x201c;mRNA,&#x201d; &#x201c;polymorphism,&#x201d; &#x201c;amplification,&#x201d; &#x201c;receptor.&#x201d; and &#x201c;activation.&#x201d; &#x201c;progression&#x201d; (cluster &#x23;1) was the second largest cluster, including keywords such as &#x201c;invasion,&#x201d; &#x201c;growth,&#x201d; &#x201c;signature,&#x201d; &#x201c;circRNA,&#x201d; and &#x201c;cancer.&#x201d; Followed by &#x201c;lncRNA&#x201d; (cluster &#x23;2), including keywords such as &#x201c;mechanism,&#x201d; &#x201c;ceRNA,&#x201d; &#x201c;mesenchymal transition,&#x201d; &#x201c;chromatin,&#x201d; and &#x201c;sequence.&#x201d;</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>The co-occurrence map <bold>(A)</bold> and burst detection <bold>(B)</bold> of keywords related to ncRNA research in PC from 2004 to 2023. Each node represents a filtered co-occurring keyword, with the size of the node indicating its co-occurrence frequency. Each link between two nodes indicates a co-occurrence relationship between the respective keywords. Nodes with purple rings indicate higher centrality, highlighting their importance within the network. Both the data and figures were generated using CiteSpace.</p>
</caption>
<graphic xlink:href="fphar-15-1483186-g005.tif"/>
</fig>
<p>Burst detection of keywords is employed to identify new or rapidly increasing keywords, which may represent cutting-edge topics or novel areas of research. By using CiteSpace, we obtained the top 10 keywords with the strongest bursts (<xref ref-type="fig" rid="F5">Figure 5B</xref>). The top three keywords with the strongest burst were &#x201c;circRNA&#x201d; (19.52), &#x201c;gene&#x201d; (18.64), and &#x201c;signature&#x201d; (14.52). Notably, the keywords &#x201c;circRNA,&#x201d; &#x201c;EVs,&#x201d; and &#x201c;exosome&#x201d; continued to show significant burst activity in 2023, indicating that these topics are key directions for future research. In addition, we extracted all miRNAs, lncRNAs, and circRNAs from the keywords, and merged and standardized similar miRNAs. <xref ref-type="table" rid="T6">Table 6</xref> lists the frequently occurring miRNAs, lncRNAs, and circRNAs, all of which have been confirmed to play significant roles in the development of PC.</p>
<table-wrap id="T6" position="float">
<label>TABLE 6</label>
<caption>
<p>Important miRNAs, lncRNAs, and circRNAs in PC from 2004 to 2023.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th colspan="2" align="center">ncRNA</th>
<th align="center">Expression</th>
<th align="center">Gene Target(s)</th>
<th align="center">Function(s)</th>
<th align="center">Reference</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td rowspan="11" align="center">miRNA</td>
<td align="center">miR-21</td>
<td align="center">&#x2191;</td>
<td align="center">p57Kip2, IRS1, SREBP-1, BTG2, TGFBR2</td>
<td align="center">Cell proliferation, lipogenesis, EMT, migration</td>
<td align="center">
<xref ref-type="bibr" rid="B19">Coppola et al. (2013)</xref>, <xref ref-type="bibr" rid="B60">Mishra et al. (2014a)</xref>, <xref ref-type="bibr" rid="B61">Mishra et al. (2014b)</xref>, and <xref ref-type="bibr" rid="B48">Kanagasabai et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">miR-200</td>
<td align="center">&#x2193;</td>
<td align="center">SNAI2, Kaiso, ZEB1</td>
<td align="center">EMT</td>
<td align="center">
<xref ref-type="bibr" rid="B57">Liu et al. (2013)</xref> and <xref ref-type="bibr" rid="B1">Abisoye-Ogunniyan et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="center">miR-375</td>
<td align="center">&#x2191;</td>
<td align="center">SEC23A, YAP1, PTPN4</td>
<td align="center">Cell proliferation, migration, invasion, apoptosis, chemo-resistance</td>
<td align="center">
<xref ref-type="bibr" rid="B91">Szczyrba et al. (2011)</xref>, <xref ref-type="bibr" rid="B105">Wang et al. (2016)</xref>, and <xref ref-type="bibr" rid="B26">Gan et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">miR-34</td>
<td align="center">&#x2193;</td>
<td align="center">AKT, p53</td>
<td align="center">Cell proliferation, migration, invasion, apoptosis, EMT, joint regulation of stem cell compartment</td>
<td align="center">
<xref ref-type="bibr" rid="B59">Majid et al. (2013)</xref> and <xref ref-type="bibr" rid="B17">Cheng et al. (2014)</xref>
</td>
</tr>
<tr>
<td align="center">miR-145</td>
<td align="center">&#x2193;</td>
<td align="center">MELK, NCAPG, BUB1, CDK1, MYC, RAS, ERG</td>
<td align="center">Cell proliferation, migration, invasion</td>
<td align="center">
<xref ref-type="bibr" rid="B35">Hart et al. (2013)</xref>, <xref ref-type="bibr" rid="B31">Goto et al. (2017)</xref>, and <xref ref-type="bibr" rid="B41">Iscaife et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="center">miR-141</td>
<td align="center">&#x2193;</td>
<td align="center">CDC42, CDC42EP3, RAC1, ARPC5, CD44, EZH2, TRAF5, TRAF6</td>
<td align="center">Cell proliferation, migration, invasion, CSC properties, EMT, bone metastasis</td>
<td align="center">
<xref ref-type="bibr" rid="B39">Huang et al. (2017)</xref> and <xref ref-type="bibr" rid="B56">Liu et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="center">miR-205</td>
<td align="center">&#x2193;</td>
<td align="center">SQLE, &#x394;Np63&#x3b1;, ZEB1/2, PKC&#x3b5;, RHPN2</td>
<td align="center">Cholesterol biosynthesis, basement membrane maintenance, cell proliferation, migration, invasion, apoptosis, EMT, radiosensitivity</td>
<td align="center">
<xref ref-type="bibr" rid="B28">Gandellini et al. (2009)</xref>, <xref ref-type="bibr" rid="B29">Gandellini et al. (2012)</xref>, <xref ref-type="bibr" rid="B21">El Bezawy et al. (2019)</xref>, <xref ref-type="bibr" rid="B44">Jiang et al. (2019)</xref>, and <xref ref-type="bibr" rid="B47">Kalogirou et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">miR-1</td>
<td align="center">&#x2193;</td>
<td align="center">SNAI2, FN1, LASP1, XPO6, TWIST1, E2F5, PFTK1</td>
<td align="center">Cell proliferation, EMT, bone metastasis</td>
<td align="center">
<xref ref-type="bibr" rid="B40">Hudson et al. (2012)</xref>, <xref ref-type="bibr" rid="B57">Liu et al. (2013)</xref>, <xref ref-type="bibr" rid="B11">Chang et al. (2015)</xref>, and <xref ref-type="bibr" rid="B50">Li et al. (2018a)</xref>
</td>
</tr>
<tr>
<td align="center">miR-143</td>
<td align="center">&#x2193;</td>
<td align="center">AKT1, KLK2, KRAS</td>
<td align="center">Cell proliferation, migration, EMT, chemo-resistance</td>
<td align="center">
<xref ref-type="bibr" rid="B110">Xu et al. (2011)</xref>, <xref ref-type="bibr" rid="B18">Chu et al. (2016)</xref>, and <xref ref-type="bibr" rid="B5">Armstrong et al. (2023)</xref>
</td>
</tr>
<tr>
<td align="center">miR-17</td>
<td align="center">&#x2191;</td>
<td align="center">TIMP3</td>
<td align="center">Cell proliferation, migration, invasion</td>
<td align="center">
<xref ref-type="bibr" rid="B114">Yang et al. (2013)</xref> and <xref ref-type="bibr" rid="B88">Stoen et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">miR-182</td>
<td align="center">&#x2191;</td>
<td align="center">MITF</td>
<td align="center">Cell proliferation, migration, invasion, apoptosis, EMT</td>
<td align="center">
<xref ref-type="bibr" rid="B101">Wang et al. (2018)</xref> and <xref ref-type="bibr" rid="B86">Stafford and McKenna (2023)</xref>
</td>
</tr>
<tr>
<td rowspan="10" align="center">lncRNA</td>
<td align="center">lncRNA PCA3</td>
<td align="center">&#x2191;</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="center">lncRNA HOTAIR</td>
<td align="center">&#x2191;</td>
<td align="center">EZH2/miR-193a, REST, AR</td>
<td align="center">Cell proliferation, migration, invasion, apoptosis, trimethylation, neuroendocrine differentiation</td>
<td align="center">
<xref ref-type="bibr" rid="B122">Zhang et al. (2015)</xref>, <xref ref-type="bibr" rid="B54">Ling et al. (2017)</xref>, and <xref ref-type="bibr" rid="B12">Chang et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="center">lncRNA PCAT1</td>
<td align="center">&#x2191;</td>
<td align="center">PHLPP/FKBP51/IKK&#x3b1;, miR-145-5p/FSCN1</td>
<td align="center">Cell proliferation, migration, invasion, apoptosis</td>
<td align="center">
<xref ref-type="bibr" rid="B111">Xu et al. (2017)</xref> and <xref ref-type="bibr" rid="B78">Shang et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">lncRNA MALAT1</td>
<td align="center">&#x2191;</td>
<td align="center">miR-423-5p</td>
<td align="center">Cell proliferation, migration, invasion</td>
<td align="center">
<xref ref-type="bibr" rid="B71">Ren et al. (2013)</xref> and <xref ref-type="bibr" rid="B24">Ferri et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">lncRNA PVT1</td>
<td align="center">&#x2191;</td>
<td align="center">PRC2, miR-15a-5p/KIF23</td>
<td align="center">Cell proliferation, migration, invasion, apoptosis</td>
<td align="center">
<xref ref-type="bibr" rid="B99">Videira et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">lncRNA UCA1</td>
<td align="center">&#x2191;</td>
<td align="center">miR-143/MYO6, miR-331-3p/EIF4G1, miR-204/CXCR4</td>
<td align="center">Cell proliferation, apoptosis, radiosensitivity</td>
<td align="center">
<xref ref-type="bibr" rid="B36">He et al. (2019)</xref>, <xref ref-type="bibr" rid="B38">Hu and Yang (2020)</xref>, and <xref ref-type="bibr" rid="B119">Yu et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">lncRNA H19</td>
<td align="center">&#x2191;</td>
<td align="center">PRC2</td>
<td align="center">Cell proliferation, invasion, chemo-resistance, histone modification, DNA methylation, CSC properties, neuroendocrine differentiation, chemo-resistance</td>
<td align="center">
<xref ref-type="bibr" rid="B83">Singh et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">lncRNA NEAT1</td>
<td align="center">&#x2191;</td>
<td align="center">CYCLINL1/CDK19, PSMA, CDC5L/AGRN</td>
<td align="center">Cell proliferation, bone metastasis, therapeutic resistance</td>
<td align="center">
<xref ref-type="bibr" rid="B10">Chakravarty et al. (2014)</xref>, <xref ref-type="bibr" rid="B52">Li et al. (2018b)</xref>, and <xref ref-type="bibr" rid="B106">Wen et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">lncRNA GAS5</td>
<td align="center">&#x2193;</td>
<td align="center">miR-18a, miR-21/PDCD4/PTEN, miR-1284/AKT</td>
<td align="center">Cell proliferation, apoptosis, radiosensitivity</td>
<td align="center">
<xref ref-type="bibr" rid="B113">Yang et al. (2019)</xref> and <xref ref-type="bibr" rid="B127">Zhu et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">lncRNA MEG3</td>
<td align="center">&#x2193;</td>
<td align="center">miR-9-5p/QKI-5, miR-9-5p/NDRG1</td>
<td align="center">Cell proliferation, migration, invasion, apoptosis</td>
<td align="center">
<xref ref-type="bibr" rid="B107">Wu et al. (2019)</xref> and <xref ref-type="bibr" rid="B53">Lian et al. (2024)</xref>
</td>
</tr>
<tr>
<td rowspan="7" align="center">circRNA</td>
<td align="center">Hsa_circ_0003258</td>
<td align="center">&#x2191;</td>
<td align="center">miR-653-5p/ARHGAP5, IGF2BP3/HDAC4</td>
<td align="center">migration, invasion, EMT</td>
<td align="center">
<xref ref-type="bibr" rid="B121">Yu et al. (2022b)</xref>
</td>
</tr>
<tr>
<td align="center">circSMARCC1</td>
<td align="center">&#x2191;</td>
<td align="center">miR-1322/CCL20/CCR6</td>
<td align="center">Cell proliferation, migration, invasion, EMT, TAMs infiltration</td>
<td align="center">
<xref ref-type="bibr" rid="B109">Xie et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">circSPON2</td>
<td align="center">&#x2191;</td>
<td align="center">miR-331-3p/PRMT5/CAMK2N1</td>
<td align="center">Cell proliferation, migration, invasion</td>
<td align="center">
<xref ref-type="bibr" rid="B115">Yao et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">circARHGAP29</td>
<td align="center">&#x2191;</td>
<td align="center">IGF2BP2/c-Myc/LDHA</td>
<td align="center">Chemo-resistance, glycolytic metabolism</td>
<td align="center">
<xref ref-type="bibr" rid="B45">Jiang et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">circEXOC6B</td>
<td align="center">&#x2193;</td>
<td align="center">AKAP12</td>
<td align="center">Migration, invasion</td>
<td align="center">
<xref ref-type="bibr" rid="B123">Zhang et al. (2023)</xref>
</td>
</tr>
<tr>
<td align="center">circCEMIP</td>
<td align="center">&#x2191;</td>
<td align="center">miR-1248/TM9SF4</td>
<td align="center">Migration, invasion, autophagy, anoikis resistance</td>
<td align="center">
<xref ref-type="bibr" rid="B124">Zhang et al. (2018)</xref> and <xref ref-type="bibr" rid="B120">Yu et al. (2022a)</xref>
</td>
</tr>
<tr>
<td align="center">circPDE5A</td>
<td align="center">&#x2193;</td>
<td align="center">WTAP/EIF3C/MAPK</td>
<td align="center">Migration, invasion, methylation</td>
<td align="center">
<xref ref-type="bibr" rid="B20">Ding et al. (2022)</xref>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>The data were extracted using CiteSpace.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>4 Discussion</title>
<sec id="s4-1">
<title>4.1 General information</title>
<p>With the rapid development of information technology and increased medical academic papers, bibliometrics has been applied in various medical fields and plays an irreplaceable role in quantitative analysis. In this study, we retrieved publications indexed in WoSCC over the past 20&#xa0;years and excluded records unrelated to ncRNA research in PC. Ultimately, 2,951 published articles were included in our bibliometric analysis. Between 2009 and 2023, there was a marked increase in both the total number of publications and citations concerning ncRNA research in PC, underscoring its emergence as a rapidly expanding area of interest. China had the highest number of publications and the second-highest number of citations, which shows its significant contribution in this field. As the most influential country, the United States collaborated with 26 countries/regions and maintained its closest partnership with China. In terms of institutional distribution, Fudan University, which had the highest number of publications, primarily collaborated with the Naval Medical University, Tongji University, and Chinese Academy of Sciences. The research focus of these institutions mainly revolves around understanding the mechanisms by which miRNAs (<xref ref-type="bibr" rid="B51">Li et al., 2014</xref>; <xref ref-type="bibr" rid="B108">Xiang et al., 2015</xref>), lncRNAs (<xref ref-type="bibr" rid="B116">Yao et al., 2020</xref>), and circRNAs (<xref ref-type="bibr" rid="B49">Kong et al., 2021</xref>) contribute to the progression of PC. According to the author analysis, Rajvir Dahiya was the most active and influential author in this field.</p>
<p>Additionally, we identified the top 10 most cited articles in ncRNA research related to PC. The most cited paper was published in <italic>Nature</italic> by <xref ref-type="bibr" rid="B30">Gao et al. (2009)</xref>, which was groundbreaking in linking changes in miR-23a/b expression and glutamine metabolism to PC progression and proposed that c-Myc plays a crucial role in regulating crucial metabolic pathways in PC. The paper with the highest annual citation frequency was published by <xref ref-type="bibr" rid="B100">Vo et al. (2019)</xref> in 2019 in <italic>Cell</italic>, which highlighted the potential of circRNAs as diagnostic biomarkers and therapeutic targets for PC.</p>
</sec>
<sec id="s4-2">
<title>4.2 Knowledge base</title>
<p>We further explored the theoretical foundations of PC-related ncRNA research through co-citation analysis of the references. Through CiteSpace clustering analysis, all co-cited references were categorized into a network map containing 10 clusters with diverse labels, where &#x201c;EVs&#x201d; (cluster &#x23;0), &#x201c;circRNA&#x201d; (cluster &#x23;2), and &#x201c;ceRNA&#x201d; (cluster &#x23;4) reflected the current research trends. The top 10 frequently co-cited references included four epidemiological studies and six foundational studies. These epidemiological findings consistently highlighted PC as a leading cause of cancer-related deaths in men and a significant public health concern in China (<xref ref-type="bibr" rid="B80">Siegel et al., 2014</xref>; <xref ref-type="bibr" rid="B15">Chen et al., 2016</xref>; <xref ref-type="bibr" rid="B81">Siegel et al., 2017</xref>; <xref ref-type="bibr" rid="B89">Sung et al., 2021</xref>). Among the six foundational studies, four investigated microRNA profiles in PC (<xref ref-type="bibr" rid="B69">Porkka et al., 2007</xref>; <xref ref-type="bibr" rid="B4">Ambs et al., 2008</xref>; <xref ref-type="bibr" rid="B67">Ozen et al., 2008</xref>; <xref ref-type="bibr" rid="B76">Schaefer et al., 2010</xref>), whereas the other two focused on exploring the molecular and genomic characteristics of the disease (<xref ref-type="bibr" rid="B95">Taylor et al., 2010</xref>; <xref ref-type="bibr" rid="B64">Network, 2015</xref>). Moreover, we identified the top 15 popular references in PC-related ncRNA research based on citation bursts, which include most of the highly co-cited references mentioned above. It is worth noting that the study by <xref ref-type="bibr" rid="B62">Mitchell et al. (2008)</xref> underscored the potential of circulating miRNAs in serum or plasma as stable blood-based biomarkers for cancer classification and prognostication, specifically demonstrating that miR-141 effectively distinguished PC patients from healthy controls. This research provided the first strong evidence supporting the diagnostic utility of circulating miRNAs in PC. <xref ref-type="bibr" rid="B72">Ribas et al. (2009)</xref> were the first to discover that high expression of miR-21 promoted the growth of PC and conferred castration resistance, while inhibition of miR-21 reduced androgen-driven proliferation of PC cells. This study provided crucial molecular insights into targeting miRNAs for the treatment of PC. In summary, co-citation analysis of the references enables us to better understand the knowledge structure of PC-related ncRNAs and to identify the core references within this field.</p>
</sec>
<sec id="s4-3">
<title>4.3 Research hotspots</title>
<p>To explore the research hotspots in PC-related ncRNAs, we analyzed the keywords from 2,951 articles. High-frequency keywords with co-occurrence rates exceeding 500 included &#x201c;PC,&#x201d; &#x201c;expression,&#x201d; &#x201c;miRNA,&#x201d; &#x201c;proliferation,&#x201d; &#x201c;metastasis,&#x201d; and &#x201c;progression,&#x201d; indicating that research primarily focused on the molecular mechanisms of miRNAs in PC proliferation and metastasis. Commonly mentioned miRNAs included miR-21, miR-200, miR-375, miR-34, miR-145, miR-141, miR-205, miR-1, miR-143, miR-17, and miR-182. Aside from &#x201c;miRNA,&#x201d; &#x201c;lncRNA&#x201d; and &#x201c;circRNA&#x201d; were also high-frequency keywords associated with ncRNAs, highlighting their significant relevance in the field of PC. We also used CiteSpace for keyword burst detection, which revealed that recent emergent keywords include &#x201c;circRNA,&#x201d; &#x201c;EVs,&#x201d; and &#x201c;exosome,&#x201d; all of which represent cutting-edge areas in ncRNA research related to PC. Here, we provide a brief discussion on the potential of circRNAs and EVs in PC.</p>
<sec id="s4-3-1">
<title>4.3.1 circRNAs</title>
<p>Early detection of PC remains crucial in reducing cancer-related mortality in men. The identification of potential cancer biomarkers significantly enhances the diagnosis and ongoing monitoring of PC, thereby improving patient outcomes. PSA liquid biopsy is the most common method for PC detection. However, its limited specificity in distinguishing between benign prostatic hyperplasia (BPH) and PC poses significant challenges for early detection and diagnosis (<xref ref-type="bibr" rid="B87">Stenman et al., 1999</xref>). circRNA was first discovered in RNA viruses in 1976 and was initially considered as splicing noise based on its biogenesis (<xref ref-type="bibr" rid="B75">Sanger et al., 1976</xref>). Until recent years, the rapid development of RNA sequencing technology has led to the identification of numerous circRNAs in eukaryotes, offering promising insights for the discovery of novel PC-related biomarkers based on liquid biopsies (<xref ref-type="bibr" rid="B103">Wang et al., 2014</xref>; <xref ref-type="bibr" rid="B58">Maass et al., 2017</xref>). As a newly discovered, abundant, and conserved class of ncRNAs, circRNAs originate from precursor mRNA and are characterized by their covalently closed loop structure formed through backsplicing (<xref ref-type="bibr" rid="B43">Jeck and Sharpless, 2014</xref>). With a unique structure lacking free ends, circRNAs are less exposed to exoribonuclease degradation (<xref ref-type="bibr" rid="B43">Jeck and Sharpless, 2014</xref>). This stability enables their reliable presence in plasma, urine, and saliva, reinforcing their potential as ideal circulating materials for liquid biopsies. Several investigations have emphasized the potential of circRNAs as biomarkers for PC. By utilizing exome capture RNA sequencing, <xref ref-type="bibr" rid="B100">Vo et al. (2019)</xref> established the MiOncoCirc database composed of circRNAs detected in tumor tissues, and identified 1,092 circRNAs in urine samples from PC patients. <xref ref-type="bibr" rid="B14">Chen et al. (2019)</xref> performed ultra-deep non-poly-A RNA sequencing on tumor samples from 144 patients with localized PC, revealing 76,311 distinct circRNAs. Among these, 171 circRNAs were identified as being essential for the proliferation of PC cells (<xref ref-type="bibr" rid="B14">Chen et al., 2019</xref>). These transcriptional profiles contribute to advancing the application of circRNAs in the diagnostic medicine of PC.</p>
<p>Furthermore, since circRNAs were first characterized as transcriptional regulators that control the miRNA-mRNA axis, an increasing body of research have preliminarily confirmed their critical roles in the epigenetic regulation associated with PC (<xref ref-type="bibr" rid="B34">Hansen et al., 2013</xref>; <xref ref-type="bibr" rid="B126">Zhou et al., 2021</xref>). <xref ref-type="bibr" rid="B121">Yu et al. (2022b)</xref> first observed the overexpression of hsa_circ_0003258 in human PC tissues, which was associated with the aggressive progression of the disease. Subsequent investigation revealed that hsa_circ_0003258 enhances the expression of Rho GTPase activating protein 5 by sponging miR-653-5p and forming a complex with insulin-like growth factor 2 mRNA binding protein 3 to stabilize HDAC4 mRNA. This interaction activates the ERK signaling pathway, accelerating the epithelial-mesenchymal transition (EMT) and ultimately promoting PC metastasis (<xref ref-type="bibr" rid="B121">Yu et al., 2022b</xref>). <xref ref-type="bibr" rid="B109">Xie et al. (2022)</xref> found that circSMARCC1 was significantly upregulated in the plasma and tissues of PC patients, promoting tumor proliferation and metastasis. Mechanistically, circSMARCC1 sponges miR-1322 to regulate the expression of CC-chemokine ligand 20 (CCL20), which activates PC cell proliferation and EMT. Additionally, circSMARCC1 induces the infiltration of tumor-associated macrophages and M2 polarization through the CCL20-CCR6 axis, thereby facilitating the progression of PC. <xref ref-type="bibr" rid="B120">Yu et al. (2022a)</xref> reported that the upregulation of circCEMIP in PC tissues promoted the invasion and metastasis of PC cells. CircCEMIP functions as a ceRNA for miR-1248, reducing the inhibitory effects of miR-1248 on its downstream target, transmembrane 9 superfamily member 4, which induces mTOR phosphorylation-mediated anoikis resistance (<xref ref-type="bibr" rid="B120">Yu et al., 2022a</xref>). In addition to serving as miRNA sponges, circRNAs interact with RNA-binding proteins and even participate in protein-coding processes, thus modulating the pathological processes of PC. <xref ref-type="bibr" rid="B23">Feng et al. (2019)</xref> identified that circ0005276, upregulated in PC tissues, promoted the proliferation, migration, and EMT of PC cells by interacting with the RNA-binding protein FUS to activate the transcription of X-linked inhibitor of apoptosis protein. <xref ref-type="bibr" rid="B104">Wang et al. (2024)</xref> discovered that the protein-coding circRNA circCCDC7 was significantly downregulated in PC patients and indicated that it upregulates FLRT3 by encoding the secretory protein circCCDC7-180aa, thereby inhibiting PC cell activity and suggesting its potential role as a tumor suppressor in PC. These studies highlight the critical involvement of circRNAs in the proliferation, metastasis, and treatment resistance associated with PC. Further exploration of circRNAs will enhance our understanding of the pathogenic mechanisms underlying PC and provide therapeutic strategies for future clinical applications.</p>
</sec>
<sec id="s4-3-2">
<title>4.3.2 EVs</title>
<p>EVs are small vesicles naturally released by all cell types into the extracellular space, initially believed to be membranous structures derived from cells for the purpose of clearing metabolic waste (<xref ref-type="bibr" rid="B97">van Niel et al., 2018</xref>). Subsequently, extensive research has uncovered that EVs, particularly exosomes, participate in various intercellular communication processes and have emerged as a prominent area of interest in biomedicine and bioengineering (<xref ref-type="bibr" rid="B97">van Niel et al., 2018</xref>; <xref ref-type="bibr" rid="B46">Kalluri and LeBleu, 2020</xref>). As nanoparticles encapsulated by a lipid bilayer membrane, EVs function as optimal carriers for safely transporting ncRNAs, playing a pivotal role in PC progression and metastasis by transferring these biomolecules to target cells (<xref ref-type="bibr" rid="B63">Mugoni et al., 2022</xref>). Liquid biopsies based on ncRNAs in EVs provide a non-invasive alternative to tissue biopsies, offering an abundant source of biological material and enabling the identification of potential tumor markers that can inform the staging and risk prognosis of PC (<xref ref-type="bibr" rid="B33">Hamed et al., 2024</xref>; <xref ref-type="bibr" rid="B37">Hu et al., 2024</xref>). The miRNA family represents one of the most frequently identified classes of ncRNAs linked to EVs. In a study comparing blood samples from 102 PC patients with those of 50 healthy controls, <xref ref-type="bibr" rid="B85">Souza et al. (2017)</xref> found that miR-200b levels in circulating EVs were associated with PSA levels exceeding 10&#xa0;ng/mL and bone metastasis, whereas miR-200c expression was associated with Gleason score. Similarly, miR-424 (<xref ref-type="bibr" rid="B3">Albino et al., 2021</xref>) and miR-1246 (<xref ref-type="bibr" rid="B6">Bhagirath et al., 2018</xref>) in circulating EVs from PC patients were correlated with the metastatic spread of tumor cells. Some researchers have attached importance to the value of EVs in predicting the efficacy of drug treatment and radiotherapy in PC patients. For example, <xref ref-type="bibr" rid="B32">Guo et al. (2020)</xref> identified miR-423-3p as a potential biomarker for early prediction of castration resistance by analyzing plasma exosomal miRNAs in PC patients and those with CRPC after ADT. <xref ref-type="bibr" rid="B105">Wang et al. (2016)</xref> showed that elevated levels of miR-375 were involved in the chemo-resistance to docetaxel in metastatic CRPC patients and were significantly associated with their overall survival. Additionally, <xref ref-type="bibr" rid="B118">Yu et al. (2018)</xref> found that 57 miRNAs in serum exosomes exhibited significant changes following carbon ion radiotherapy in localized PC patients, with miR-654-3p and miR-379-5p emerging as potential predictors of therapeutic response to this treatment.</p>
<p>It is evident that PC-derived EVs function as crucial carriers of ncRNAs, facilitating the progression of PC through intercellular communication, including tumor proliferation, metastasis, angiogenesis, immune evasion, and drug resistance (<xref ref-type="bibr" rid="B37">Hu et al., 2024</xref>). Recent studies have identified several miRNAs, lncRNAs, and circRNAs within PC-derived EVs as potential inhibitory targets in PC therapy, offering new insights into precision medicine for this disease (<xref ref-type="bibr" rid="B2">Aghdam et al., 2019</xref>; <xref ref-type="bibr" rid="B112">Xu et al., 2019</xref>; <xref ref-type="bibr" rid="B126">Zhou et al., 2021</xref>). Additionally, compared to traditional delivery vehicles, EVs demonstrate superior biocompatibility and delivery efficiency, and their intrinsic advantages of naturally homing to tumor cells offer prospects for PC therapeutic strategies targeting EVs (<xref ref-type="bibr" rid="B37">Hu et al., 2024</xref>). Inhibiting the secretion of PC-derived EVs could be a critical step in reducing communication within the tumor microenvironment. <xref ref-type="bibr" rid="B96">Urabe et al. (2020)</xref> conducted a high-throughput miRNA-based screening using the ExoScreen assay and identified miR-26a as a regulator of EV secretion in PC cells. The associated mechanism involved the modulation of the SHC4, PFDN4, and CHORDC1 genes. Moreover, limited data confirmed that certain normal cells exhibit antitumor activity against PC. For instance, adipose-derived stromal cells release EVs containing miR-145, which suppress the proliferation of PC cells and induce apoptosis (<xref ref-type="bibr" rid="B92">Takahara et al., 2016</xref>). Exosomal miR-205 and miR-99b-5p derived from human bone marrow mesenchymal stem cells inhibit the proliferation, invasion, and migration of PC cells (<xref ref-type="bibr" rid="B44">Jiang et al., 2019</xref>). A deeper understanding of the roles of ncRNAs in EVs secreted by different cell types in PC paves the way for novel therapeutic strategies based on engineered EVs.</p>
</sec>
</sec>
<sec id="s4-4">
<title>4.4 Limitations</title>
<p>In this study, we conducted the first bibliometric analysis using data from the WoSCC to objectively assess the research trends and current landscape in the field of PC-related ncRNAs. While our approach offers valuable insights, it is important to recognize certain limitations. First, although WoSCC is widely considered the premier database for bibliometric studies, there remains the possibility that some relevant articles were not captured, potentially introducing minor biases in our findings. Moreover, our analysis was based on data from publications spanning 2004 to 2023, limiting its ability to reflect the most recent advances in the field. Third, the nature of bibliometric analysis tends to prioritize highly cited mainstream research, potentially overlooking less cited but innovative studies. Nevertheless, we believe these limitations do not substantially diminish the relevance or contributions of the publications included in our analysis to the field.</p>
</sec>
</sec>
<sec sec-type="conclusion" id="s5">
<title>5 Conclusion</title>
<p>This study presented a comprehensive bibliometric analysis of 2,951 articles on PC-related ncRNAs over the past 20&#xa0;years. The global publication output in this field had seen rapid growth since 2011, indicating its emergence as a focal point of scholarly attention. China led in publication output, while the United States was the most influential nation, engaging in collaborating with 26 other countries. Rajvir Dahiya stood out as the most prolific and influential author. The research landscape of PC- related ncRNAs was predominantly focused on elucidating the molecular mechanisms by which miRNAs drive PC proliferation and metastasis. Additionally, circRNAs and EVs are emerging as pivotal areas of future exploration, offering promising avenues for advancing the precise diagnosis and targeted treatment of PC.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="s6">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="sec" rid="s11">Supplementary Material</xref>, further inquiries can be directed to the corresponding author.</p>
</sec>
<sec sec-type="author-contributions" id="s7">
<title>Author contributions</title>
<p>Y-LZ: Conceptualization, Data curation, Writing&#x2013;original draft, Writing&#x2013;review and editing. W-LY: Conceptualization, Writing&#x2013;review and editing, Writing&#x2013;original draft. S-HC: Conceptualization, Funding acquisition, Writing&#x2013;review and editing, Supervision. PW: Data curation, Writing&#x2013;original draft. J-WF: Data curation, Methodology, Writing&#x2013;original draft. J-QZ: Data curation, Methodology, Software, Writing&#x2013;original draft. J-YZ: Data curation, Methodology, Writing&#x2013;review and editing.</p>
</sec>
<sec sec-type="funding-information" id="s8">
<title>Funding</title>
<p>The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Jiangxi Provincial Key Laboratory of Traditional Chinese Medicine Andrology (KP202102007).</p>
</sec>
<sec sec-type="COI-statement" id="s9">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s10">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s11">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2024.1483186/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fphar.2024.1483186/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="Table1.docx" id="SM1" mimetype="application/docx" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Table2.docx" id="SM2" mimetype="application/docx" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Table5.docx" id="SM3" mimetype="application/docx" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Table3.docx" id="SM4" mimetype="application/docx" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Image2.png" id="SM5" mimetype="application/png" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Table4.docx" id="SM6" mimetype="application/docx" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Image1.png" id="SM7" mimetype="application/png" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Image3.png" id="SM8" mimetype="application/png" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abisoye-Ogunniyan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ghebremedhin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Salam</surname>
<given-names>A. B.</given-names>
</name>
<name>
<surname>Karanam</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Theodore</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Transcriptional repressor Kaiso promotes epithelial to mesenchymal transition and metastasis in prostate cancer through direct regulation of miR-200c</article-title>. <source>Cancer Lett.</source> <volume>431</volume>, <fpage>1</fpage>&#x2013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2018.04.044</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aghdam</surname>
<given-names>S. G.</given-names>
</name>
<name>
<surname>Ebrazeh</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hemmatzadeh</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Seyfizadeh</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Shabgah</surname>
<given-names>A. G.</given-names>
</name>
<name>
<surname>Azizi</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>The role of microRNAs in prostate cancer migration, invasion, and metastasis</article-title>. <source>J. Cell Physiol.</source> <volume>234</volume> (<issue>7</issue>), <fpage>9927</fpage>&#x2013;<lpage>9942</lpage>. <pub-id pub-id-type="doi">10.1002/jcp.27948</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Albino</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Falcione</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Uboldi</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Temilola</surname>
<given-names>D. O.</given-names>
</name>
<name>
<surname>Sandrini</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Merulla</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Circulating extracellular vesicles release oncogenic miR-424 in experimental models and patients with aggressive prostate cancer</article-title>. <source>Commun. Biol.</source> <volume>4</volume> (<issue>1</issue>), <fpage>119</fpage>. <pub-id pub-id-type="doi">10.1038/s42003-020-01642-5</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ambs</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Prueitt</surname>
<given-names>R. L.</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hudson</surname>
<given-names>R. S.</given-names>
</name>
<name>
<surname>Howe</surname>
<given-names>T. M.</given-names>
</name>
<name>
<surname>Petrocca</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2008</year>). <article-title>Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer</article-title>. <source>Cancer Res.</source> <volume>68</volume> (<issue>15</issue>), <fpage>6162</fpage>&#x2013;<lpage>6170</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.Can-08-0144</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Armstrong</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Willoughby</surname>
<given-names>C. E.</given-names>
</name>
<name>
<surname>McKenna</surname>
<given-names>D. J.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Targeting of AKT1 by miR-143-3p suppresses epithelial-to-mesenchymal transition in prostate cancer</article-title>. <source>Cells</source> <volume>12</volume> (<issue>18</issue>), <fpage>2207</fpage>. <pub-id pub-id-type="doi">10.3390/cells12182207</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bhagirath</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>T. L.</given-names>
</name>
<name>
<surname>Bucay</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Sekhon</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Majid</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Shahryari</surname>
<given-names>V.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>microRNA-1246 is an exosomal biomarker for aggressive prostate cancer</article-title>. <source>Cancer Res.</source> <volume>78</volume> (<issue>7</issue>), <fpage>1833</fpage>&#x2013;<lpage>1844</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.Can-17-2069</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bray</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Laversanne</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sung</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ferlay</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Siegel</surname>
<given-names>R. L.</given-names>
</name>
<name>
<surname>Soerjomataram</surname>
<given-names>I.</given-names>
</name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>. <source>CA Cancer J. Clin.</source> <volume>74</volume> (<issue>3</issue>), <fpage>229</fpage>&#x2013;<lpage>263</lpage>. <pub-id pub-id-type="doi">10.3322/caac.21834</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brosnan</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Voinnet</surname>
<given-names>O.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>The long and the short of noncoding RNAs</article-title>. <source>Curr. Opin. Cell Biol.</source> <volume>21</volume> (<issue>3</issue>), <fpage>416</fpage>&#x2013;<lpage>425</lpage>. <pub-id pub-id-type="doi">10.1016/j.ceb.2009.04.001</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cai</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>X. L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X. A.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>D. H.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Current therapy and drug resistance in metastatic castration-resistant prostate cancer</article-title>. <source>Drug Resist Updat</source> <volume>68</volume>, <fpage>100962</fpage>. <pub-id pub-id-type="doi">10.1016/j.drup.2023.100962</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chakravarty</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sboner</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Nair</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Giannopoulou</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hennig</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer</article-title>. <source>Nat. Commun.</source> <volume>5</volume>, <fpage>5383</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms6383</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname>
<given-names>Y. S.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W. Y.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Sheppard-Tillman</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y. N.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>EGF receptor promotes prostate cancer bone metastasis by downregulating miR-1 and activating TWIST1</article-title>. <source>Cancer Res.</source> <volume>75</volume> (<issue>15</issue>), <fpage>3077</fpage>&#x2013;<lpage>3086</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.Can-14-3380</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname>
<given-names>Y. T.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>T. P.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>J. T.</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>Y. L.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>S. Y.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>HOTAIR is a REST-regulated lncRNA that promotes neuroendocrine differentiation in castration resistant prostate cancer</article-title>. <source>Cancer Lett.</source> <volume>433</volume>, <fpage>43</fpage>&#x2013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2018.06.029</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Searching for intellectual turning points: progressive knowledge domain visualization</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source> <volume>101</volume> (<issue>Suppl. 1</issue>), <fpage>5303</fpage>&#x2013;<lpage>5310</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0307513100</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Livingstone</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Soares</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Jeon</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Widespread and functional RNA circularization in localized prostate cancer</article-title>. <source>Cell</source> <volume>176</volume> (<issue>4</issue>), <fpage>831</fpage>&#x2013;<lpage>843</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2019.01.025</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Baade</surname>
<given-names>P. D.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Bray</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Cancer statistics in China, 2015</article-title>. <source>CA Cancer J. Clin.</source> <volume>66</volume> (<issue>2</issue>), <fpage>115</fpage>&#x2013;<lpage>132</lpage>. <pub-id pub-id-type="doi">10.3322/caac.21338</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Lei</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Bibliometric analysis of the global research development of bone metastases in prostate cancer: a 22-year study</article-title>. <source>Front. Oncol.</source> <volume>12</volume>, <fpage>947445</fpage>. <pub-id pub-id-type="doi">10.3389/fonc.2022.947445</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname>
<given-names>C. Y.</given-names>
</name>
<name>
<surname>Hwang</surname>
<given-names>C. I.</given-names>
</name>
<name>
<surname>Corney</surname>
<given-names>D. C.</given-names>
</name>
<name>
<surname>Flesken-Nikitin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>&#xd6;ner</surname>
<given-names>G. M.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>miR-34 cooperates with p53 in suppression of prostate cancer by joint regulation of stem cell compartment</article-title>. <source>Cell Rep.</source> <volume>6</volume> (<issue>6</issue>), <fpage>1000</fpage>&#x2013;<lpage>1007</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2014.02.023</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>A functional variant in miR-143 promoter contributes to prostate cancer risk</article-title>. <source>Arch. Toxicol.</source> <volume>90</volume> (<issue>2</issue>), <fpage>403</fpage>&#x2013;<lpage>414</lpage>. <pub-id pub-id-type="doi">10.1007/s00204-014-1396-2</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coppola</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Musumeci</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Patrizii</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cannistraci</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Addario</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Maugeri-Sacc&#xe0;</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>BTG2 loss and miR-21 upregulation contribute to prostate cell transformation by inducing luminal markers expression and epithelial-mesenchymal transition</article-title>. <source>Oncogene</source> <volume>32</volume> (<issue>14</issue>), <fpage>1843</fpage>&#x2013;<lpage>1853</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2012.194</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ding</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>circPDE5A regulates prostate cancer metastasis via controlling WTAP-dependent N6-methyladenisine methylation of EIF3C mRNA</article-title>. <source>J. Exp. Clin. Cancer Res.</source> <volume>41</volume> (<issue>1</issue>), <fpage>187</fpage>. <pub-id pub-id-type="doi">10.1186/s13046-022-02391-5</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>El Bezawy</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tinelli</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tortoreto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Doldi</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Zuco</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Folini</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>miR-205 enhances radiation sensitivity of prostate cancer cells by impairing DNA damage repair through PKC&#x3b5; and ZEB1 inhibition</article-title>. <source>J. Exp. Clin. Cancer Res.</source> <volume>38</volume> (<issue>1</issue>), <fpage>51</fpage>. <pub-id pub-id-type="doi">10.1186/s13046-019-1060-z</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feldman</surname>
<given-names>B. J.</given-names>
</name>
<name>
<surname>Feldman</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>The development of androgen-independent prostate cancer</article-title>. <source>Nat. Rev. Cancer</source> <volume>1</volume> (<issue>1</issue>), <fpage>34</fpage>&#x2013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1038/35094009</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Rong</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Circular RNA circ0005276 promotes the proliferation and migration of prostate cancer cells by interacting with FUS to transcriptionally activate XIAP</article-title>. <source>Cell Death Dis.</source> <volume>10</volume> (<issue>11</issue>), <fpage>792</fpage>. <pub-id pub-id-type="doi">10.1038/s41419-019-2028-9</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferri</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Di Biase</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bocchetti</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zappavigna</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Le Vu</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>MiR-423-5p prevents MALAT1-mediated proliferation and metastasis in prostate cancer</article-title>. <source>J. Exp. Clin. Cancer Res.</source> <volume>41</volume> (<issue>1</issue>), <fpage>20</fpage>. <pub-id pub-id-type="doi">10.1186/s13046-021-02233-w</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gallant-Behm</surname>
<given-names>C. L.</given-names>
</name>
<name>
<surname>Piper</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Seto</surname>
<given-names>A. G.</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Mustoe</surname>
<given-names>T. A.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>A MicroRNA-29 mimic (remlarsen) represses extracellular matrix expression and fibroplasia in the skin</article-title>. <source>J. Invest Dermatol</source> <volume>139</volume> (<issue>5</issue>), <fpage>1073</fpage>&#x2013;<lpage>1081</lpage>. <pub-id pub-id-type="doi">10.1016/j.jid.2018.11.007</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>MicroRNA-375 is a therapeutic target for castration-resistant prostate cancer through the PTPN4/STAT3 axis</article-title>. <source>Exp. Mol. Med.</source> <volume>54</volume> (<issue>8</issue>), <fpage>1290</fpage>&#x2013;<lpage>1305</lpage>. <pub-id pub-id-type="doi">10.1038/s12276-022-00837-6</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gandaglia</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Leni</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bray</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Fleshner</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Freedland</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Kibel</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Epidemiology and prevention of prostate cancer</article-title>. <source>Eur. Urol. Oncol.</source> <volume>4</volume> (<issue>6</issue>), <fpage>877</fpage>&#x2013;<lpage>892</lpage>. <pub-id pub-id-type="doi">10.1016/j.euo.2021.09.006</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gandellini</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Folini</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Longoni</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Pennati</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Binda</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Colecchia</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2009</year>). <article-title>miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon</article-title>. <source>Cancer Res.</source> <volume>69</volume> (<issue>6</issue>), <fpage>2287</fpage>&#x2013;<lpage>2295</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.Can-08-2894</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gandellini</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Profumo</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Casamichele</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fenderico</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Borrelli</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Petrovich</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>miR-205 regulates basement membrane deposition in human prostate: implications for cancer development</article-title>. <source>Cell Death Differ.</source> <volume>19</volume> (<issue>11</issue>), <fpage>1750</fpage>&#x2013;<lpage>1760</lpage>. <pub-id pub-id-type="doi">10.1038/cdd.2012.56</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Tchernyshyov</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>T. C.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>Y. S.</given-names>
</name>
<name>
<surname>Kita</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ochi</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2009</year>). <article-title>c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism</article-title>. <source>Nature</source> <volume>458</volume> (<issue>7239</issue>), <fpage>762</fpage>&#x2013;<lpage>765</lpage>. <pub-id pub-id-type="doi">10.1038/nature07823</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goto</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kurozumi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Arai</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nohata</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kojima</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Okato</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Impact of novel miR-145-3p regulatory networks on survival in patients with castration-resistant prostate cancer</article-title>. <source>Br. J. Cancer</source> <volume>117</volume> (<issue>3</issue>), <fpage>409</fpage>&#x2013;<lpage>420</lpage>. <pub-id pub-id-type="doi">10.1038/bjc.2017.191</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Stankiewicz</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Scandura</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>The identification of plasma exosomal miR-423-3p as a potential predictive biomarker for prostate cancer castration-resistance development by plasma exosomal miRNA sequencing</article-title>. <source>Front. Cell Dev. Biol.</source> <volume>8</volume>, <fpage>602493</fpage>. <pub-id pub-id-type="doi">10.3389/fcell.2020.602493</pub-id>
</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hamed</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Wasinger</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Malouf</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Bucci</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Prostate cancer-derived extracellular vesicles metabolic biomarkers: emerging roles for diagnosis and prognosis</article-title>. <source>J. Control Release</source> <volume>371</volume>, <fpage>126</fpage>&#x2013;<lpage>145</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2024.05.029</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hansen</surname>
<given-names>T. B.</given-names>
</name>
<name>
<surname>Jensen</surname>
<given-names>T. I.</given-names>
</name>
<name>
<surname>Clausen</surname>
<given-names>B. H.</given-names>
</name>
<name>
<surname>Bramsen</surname>
<given-names>J. B.</given-names>
</name>
<name>
<surname>Finsen</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Damgaard</surname>
<given-names>C. K.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Natural RNA circles function as efficient microRNA sponges</article-title>. <source>Nature</source> <volume>495</volume> (<issue>7441</issue>), <fpage>384</fpage>&#x2013;<lpage>388</lpage>. <pub-id pub-id-type="doi">10.1038/nature11993</pub-id>
</citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hart</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wach</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nolte</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Szczyrba</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Menon</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Taubert</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>The proto-oncogene ERG is a target of microRNA miR-145 in prostate cancer</article-title>. <source>Febs J.</source> <volume>280</volume> (<issue>9</issue>), <fpage>2105</fpage>&#x2013;<lpage>2116</lpage>. <pub-id pub-id-type="doi">10.1111/febs.12236</pub-id>
</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>LncRNA UCA1 acts as a sponge of miR-204 to up-regulate CXCR4 expression and promote prostate cancer progression</article-title>. <source>Biosci. Rep.</source> <volume>39</volume> (<issue>5</issue>). <pub-id pub-id-type="doi">10.1042/bsr20181465</pub-id>
</citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2024</year>). <article-title>The role of extracellular vesicles in the treatment of prostate cancer</article-title>. <source>Small</source> <volume>20</volume>, <fpage>e2311071</fpage>. <pub-id pub-id-type="doi">10.1002/smll.202311071</pub-id>
</citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Down-regulation of lncRNA UCA1 enhances radiosensitivity in prostate cancer by suppressing EIF4G1 expression via sponging miR-331-3p</article-title>. <source>Cancer Cell Int.</source> <volume>20</volume>, <fpage>449</fpage>. <pub-id pub-id-type="doi">10.1186/s12935-020-01538-8</pub-id>
</citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wa</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Downregulation of miR-141-3p promotes bone metastasis via activating NF-&#x3ba;B signaling in prostate cancer</article-title>. <source>J. Exp. Clin. Cancer Res.</source> <volume>36</volume> (<issue>1</issue>), <fpage>173</fpage>. <pub-id pub-id-type="doi">10.1186/s13046-017-0645-7</pub-id>
</citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hudson</surname>
<given-names>R. S.</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Esposito</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Watkins</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Hurwitz</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Yfantis</surname>
<given-names>H. G.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer</article-title>. <source>Nucleic Acids Res.</source> <volume>40</volume> (<issue>8</issue>), <fpage>3689</fpage>&#x2013;<lpage>3703</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkr1222</pub-id>
</citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iscaife</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Reis</surname>
<given-names>S. T.</given-names>
</name>
<name>
<surname>Morais</surname>
<given-names>D. R.</given-names>
</name>
<name>
<surname>Viana</surname>
<given-names>N. I.</given-names>
</name>
<name>
<surname>da Silva</surname>
<given-names>I. A.</given-names>
</name>
<name>
<surname>Pimenta</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Treating metastatic prostate cancer with microRNA-145</article-title>. <source>Apoptosis</source> <volume>23</volume> (<issue>7-8</issue>), <fpage>388</fpage>&#x2013;<lpage>395</lpage>. <pub-id pub-id-type="doi">10.1007/s10495-018-1461-z</pub-id>
</citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Janssen</surname>
<given-names>H. L.</given-names>
</name>
<name>
<surname>Reesink</surname>
<given-names>H. W.</given-names>
</name>
<name>
<surname>Lawitz</surname>
<given-names>E. J.</given-names>
</name>
<name>
<surname>Zeuzem</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rodriguez-Torres</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Treatment of HCV infection by targeting microRNA</article-title>. <source>N. Engl. J. Med.</source> <volume>368</volume> (<issue>18</issue>), <fpage>1685</fpage>&#x2013;<lpage>1694</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1209026</pub-id>
</citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jeck</surname>
<given-names>W. R.</given-names>
</name>
<name>
<surname>Sharpless</surname>
<given-names>N. E.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Detecting and characterizing circular RNAs</article-title>. <source>Nat. Biotechnol.</source> <volume>32</volume> (<issue>5</issue>), <fpage>453</fpage>&#x2013;<lpage>461</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.2890</pub-id>
</citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhuang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Human bone marrow mesenchymal stem cells-derived microRNA-205-containing exosomes impede the progression of prostate cancer through suppression of RHPN2</article-title>. <source>J. Exp. Clin. Cancer Res.</source> <volume>38</volume> (<issue>1</issue>), <fpage>495</fpage>. <pub-id pub-id-type="doi">10.1186/s13046-019-1488-1</pub-id>
</citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>EIF4A3-Induced circARHGAP29 promotes aerobic glycolysis in docetaxel-resistant prostate cancer through IGF2BP2/c-Myc/LDHA signaling</article-title>. <source>Cancer Res.</source> <volume>82</volume> (<issue>5</issue>), <fpage>831</fpage>&#x2013;<lpage>845</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.Can-21-2988</pub-id>
</citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalluri</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>LeBleu</surname>
<given-names>V. S.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>The biology, function, and biomedical applications of exosomes</article-title>. <source>Science</source> <volume>367</volume> (<issue>6478</issue>), <fpage>eaau6977</fpage>. <pub-id pub-id-type="doi">10.1126/science.aau6977</pub-id>
</citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalogirou</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Linxweiler</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Schmucker</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Snaebjornsson</surname>
<given-names>M. T.</given-names>
</name>
<name>
<surname>Schmitz</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wach</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>MiR-205-driven downregulation of cholesterol biosynthesis through SQLE-inhibition identifies therapeutic vulnerability in aggressive prostate cancer</article-title>. <source>Nat. Commun.</source> <volume>12</volume> (<issue>1</issue>), <fpage>5066</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-021-25325-9</pub-id>
</citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanagasabai</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>T. H.</given-names>
</name>
<name>
<surname>Gladoun</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Castillo-Martin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Celada</surname>
<given-names>S. I.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>MicroRNA-21 deficiency suppresses prostate cancer progression through downregulation of the IRS1-SREBP-1 signaling pathway</article-title>. <source>Cancer Lett.</source> <volume>525</volume>, <fpage>46</fpage>&#x2013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2021.09.041</pub-id>
</citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kong</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Comprehensive characterization of androgen-responsive circRNAs in prostate cancer</article-title>. <source>Life (Basel)</source> <volume>11</volume> (<issue>10</issue>), <fpage>1096</fpage>. <pub-id pub-id-type="doi">10.3390/life11101096</pub-id>
</citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>H. L.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S. G.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>Z. Q.</given-names>
</name>
<etal/>
</person-group> (<year>2018a</year>). <article-title>The putative tumour suppressor miR-1-3p modulates prostate cancer cell aggressiveness by repressing E2F5 and PFTK1</article-title>. <source>J. Exp. Clin. Cancer Res.</source> <volume>37</volume> (<issue>1</issue>), <fpage>219</fpage>. <pub-id pub-id-type="doi">10.1186/s13046-018-0895-z</pub-id>
</citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Mo</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Identification of miR-133b and RB1CC1 as independent predictors for biochemical recurrence and potential therapeutic targets for prostate cancer</article-title>. <source>Clin. Cancer Res.</source> <volume>20</volume> (<issue>9</issue>), <fpage>2312</fpage>&#x2013;<lpage>2325</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.Ccr-13-1588</pub-id>
</citation>
</ref>
<ref id="B52">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2018b</year>). <article-title>Oncogenic properties of NEAT1 in prostate cancer cells depend on the cdc5l-AGRN transcriptional regulation circuit</article-title>. <source>Cancer Res.</source> <volume>78</volume> (<issue>15</issue>), <fpage>4138</fpage>&#x2013;<lpage>4149</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.Can-18-0688</pub-id>
</citation>
</ref>
<ref id="B53">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lian</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>Q.</given-names>
</name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Long noncoding RNA MEG3 regulates cell proliferation and apoptosis by disrupting microRNA-9-5p-mediated inhibition of NDRG1 in prostate cancer</article-title>. <source>Aging (Albany NY)</source> <volume>16</volume> (<issue>2</issue>), <fpage>1938</fpage>&#x2013;<lpage>1951</lpage>. <pub-id pub-id-type="doi">10.18632/aging.205472</pub-id>
</citation>
</ref>
<ref id="B54">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ling</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Tao</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Guan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>You</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Involvement of aberrantly activated HOTAIR/EZH2/miR-193a feedback loop in progression of prostate cancer</article-title>. <source>J. Exp. Clin. Cancer Res.</source> <volume>36</volume> (<issue>1</issue>), <fpage>159</fpage>. <pub-id pub-id-type="doi">10.1186/s13046-017-0629-7</pub-id>
</citation>
</ref>
<ref id="B55">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Litwin</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>H. J.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>The diagnosis and treatment of prostate cancer: a review</article-title>. <source>Jama</source> <volume>317</volume> (<issue>24</issue>), <fpage>2532</fpage>&#x2013;<lpage>2542</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2017.7248</pub-id>
</citation>
</ref>
<ref id="B56">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Chao</surname>
<given-names>H. P.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>MicroRNA-141 suppresses prostate cancer stem cells and metastasis by targeting a cohort of pro-metastasis genes</article-title>. <source>Nat. Commun.</source> <volume>8</volume>, <fpage>14270</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms14270</pub-id>
</citation>
</ref>
<ref id="B57">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Y. N.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Abou-Kheir</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Hynes</surname>
<given-names>P. G.</given-names>
</name>
<name>
<surname>Casey</surname>
<given-names>O. M.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms</article-title>. <source>Oncogene</source> <volume>32</volume> (<issue>3</issue>), <fpage>296</fpage>&#x2013;<lpage>306</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2012.58</pub-id>
</citation>
</ref>
<ref id="B58">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maass</surname>
<given-names>P. G.</given-names>
</name>
<name>
<surname>Gla&#x17e;ar</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Memczak</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Dittmar</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Hollfinger</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Schreyer</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>A map of human circular RNAs in clinically relevant tissues</article-title>. <source>J. Mol. Med. Berl.</source> <volume>95</volume> (<issue>11</issue>), <fpage>1179</fpage>&#x2013;<lpage>1189</lpage>. <pub-id pub-id-type="doi">10.1007/s00109-017-1582-9</pub-id>
</citation>
</ref>
<ref id="B59">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Majid</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Dar</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Saini</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Shahryari</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Arora</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zaman</surname>
<given-names>M. S.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways</article-title>. <source>Clin. Cancer Res.</source> <volume>19</volume> (<issue>1</issue>), <fpage>73</fpage>&#x2013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.Ccr-12-2952</pub-id>
</citation>
</ref>
<ref id="B60">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mishra</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Gowda</surname>
<given-names>P. S.</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>M. K.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>C. L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C. L.</given-names>
</name>
<etal/>
</person-group> (<year>2014a</year>). <article-title>Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (TGFBR2) expression in prostate cancer</article-title>. <source>Oncogene</source> <volume>33</volume> (<issue>31</issue>), <fpage>4097</fpage>&#x2013;<lpage>4106</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2013.374</pub-id>
</citation>
</ref>
<ref id="B61">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mishra</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>C. L.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>T. H.</given-names>
</name>
<name>
<surname>Bouamar</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>L. Z.</given-names>
</name>
</person-group> (<year>2014b</year>). <article-title>MicroRNA-21 inhibits p57Kip2 expression in prostate cancer</article-title>. <source>Mol. Cancer</source> <volume>13</volume>, <fpage>212</fpage>. <pub-id pub-id-type="doi">10.1186/1476-4598-13-212</pub-id>
</citation>
</ref>
<ref id="B62">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitchell</surname>
<given-names>P. S.</given-names>
</name>
<name>
<surname>Parkin</surname>
<given-names>R. K.</given-names>
</name>
<name>
<surname>Kroh</surname>
<given-names>E. M.</given-names>
</name>
<name>
<surname>Fritz</surname>
<given-names>B. R.</given-names>
</name>
<name>
<surname>Wyman</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Pogosova-Agadjanyan</surname>
<given-names>E. L.</given-names>
</name>
<etal/>
</person-group> (<year>2008</year>). <article-title>Circulating microRNAs as stable blood-based markers for cancer detection</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source> <volume>105</volume> (<issue>30</issue>), <fpage>10513</fpage>&#x2013;<lpage>10518</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0804549105</pub-id>
</citation>
</ref>
<ref id="B63">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mugoni</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Ciani</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nardella</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Demichelis</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Circulating RNAs in prostate cancer patients</article-title>. <source>Cancer Lett.</source> <volume>524</volume>, <fpage>57</fpage>&#x2013;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2021.10.011</pub-id>
</citation>
</ref>
<ref id="B64">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Network</surname>
<given-names>C. G. A. R.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>The molecular taxonomy of primary prostate cancer</article-title>. <source>Cell</source> <volume>163</volume> (<issue>4</issue>), <fpage>1011</fpage>&#x2013;<lpage>1025</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2015.10.025</pub-id>
</citation>
</ref>
<ref id="B65">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nicolaisen</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Bibliometrics and citation analysis: from the science citation index to cybermetrics</article-title>. <source>J. Am. Soc. Inf. Sci.</source> <volume>61</volume> (<issue>1</issue>), <fpage>205</fpage>&#x2013;<lpage>207</lpage>. <pub-id pub-id-type="doi">10.1002/asi.21181</pub-id>
</citation>
</ref>
<ref id="B66">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Noonan</surname>
<given-names>E. J.</given-names>
</name>
<name>
<surname>Place</surname>
<given-names>R. F.</given-names>
</name>
<name>
<surname>Pookot</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Basak</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Whitson</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Hirata</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2009</year>). <article-title>miR-449a targets HDAC-1 and induces growth arrest in prostate cancer</article-title>. <source>Oncogene</source> <volume>28</volume> (<issue>14</issue>), <fpage>1714</fpage>&#x2013;<lpage>1724</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2009.19</pub-id>
</citation>
</ref>
<ref id="B67">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ozen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Creighton</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Ozdemir</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ittmann</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Widespread deregulation of microRNA expression in human prostate cancer</article-title>. <source>Oncogene</source> <volume>27</volume> (<issue>12</issue>), <fpage>1788</fpage>&#x2013;<lpage>1793</lpage>. <pub-id pub-id-type="doi">10.1038/sj.onc.1210809</pub-id>
</citation>
</ref>
<ref id="B68">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pinsky</surname>
<given-names>P. F.</given-names>
</name>
<name>
<surname>Parnes</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Screening for prostate cancer</article-title>. <source>N. Engl. J. Med.</source> <volume>388</volume> (<issue>15</issue>), <fpage>1405</fpage>&#x2013;<lpage>1414</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMcp2209151</pub-id>
</citation>
</ref>
<ref id="B69">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Porkka</surname>
<given-names>K. P.</given-names>
</name>
<name>
<surname>Pfeiffer</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Waltering</surname>
<given-names>K. K.</given-names>
</name>
<name>
<surname>Vessella</surname>
<given-names>R. L.</given-names>
</name>
<name>
<surname>Tammela</surname>
<given-names>T. L.</given-names>
</name>
<name>
<surname>Visakorpi</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>MicroRNA expression profiling in prostate cancer</article-title>. <source>Cancer Res.</source> <volume>67</volume> (<issue>13</issue>), <fpage>6130</fpage>&#x2013;<lpage>6135</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.Can-07-0533</pub-id>
</citation>
</ref>
<ref id="B70">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramalho-Carvalho</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fromm</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Henrique</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Jer&#xf3;nimo</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Deciphering the function of non-coding RNAs in prostate cancer</article-title>. <source>Cancer Metastasis Rev.</source> <volume>35</volume> (<issue>2</issue>), <fpage>235</fpage>&#x2013;<lpage>262</lpage>. <pub-id pub-id-type="doi">10.1007/s10555-016-9628-y</pub-id>
</citation>
</ref>
<ref id="B71">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ren</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer</article-title>. <source>J. Urol.</source> <volume>190</volume> (<issue>6</issue>), <fpage>2278</fpage>&#x2013;<lpage>2287</lpage>. <pub-id pub-id-type="doi">10.1016/j.juro.2013.07.001</pub-id>
</citation>
</ref>
<ref id="B72">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ribas</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ni</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Haffner</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wentzel</surname>
<given-names>E. A.</given-names>
</name>
<name>
<surname>Salmasi</surname>
<given-names>A. H.</given-names>
</name>
<name>
<surname>Chowdhury</surname>
<given-names>W. H.</given-names>
</name>
<etal/>
</person-group> (<year>2009</year>). <article-title>miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth</article-title>. <source>Cancer Res.</source> <volume>69</volume> (<issue>18</issue>), <fpage>7165</fpage>&#x2013;<lpage>7169</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.Can-09-1448</pub-id>
</citation>
</ref>
<ref id="B73">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rinn</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Guttman</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>RNA Function. RNA and dynamic nuclear organization</article-title>. <source>Science</source> <volume>345</volume> (<issue>6202</issue>), <fpage>1240</fpage>&#x2013;<lpage>1241</lpage>. <pub-id pub-id-type="doi">10.1126/science.1252966</pub-id>
</citation>
</ref>
<ref id="B74">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saini</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Majid</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yamamura</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tabatabai</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Suh</surname>
<given-names>S. O.</given-names>
</name>
<name>
<surname>Shahryari</surname>
<given-names>V.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Regulatory role of mir-203 in prostate cancer progression and metastasis</article-title>. <source>Clin. Cancer Res.</source> <volume>17</volume> (<issue>16</issue>), <fpage>5287</fpage>&#x2013;<lpage>5298</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.Ccr-10-2619</pub-id>
</citation>
</ref>
<ref id="B75">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanger</surname>
<given-names>H. L.</given-names>
</name>
<name>
<surname>Klotz</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Riesner</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Gross</surname>
<given-names>H. J.</given-names>
</name>
<name>
<surname>Kleinschmidt</surname>
<given-names>A. K.</given-names>
</name>
</person-group> (<year>1976</year>). <article-title>Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source> <volume>73</volume> (<issue>11</issue>), <fpage>3852</fpage>&#x2013;<lpage>3856</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.73.11.3852</pub-id>
</citation>
</ref>
<ref id="B76">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schaefer</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mollenkopf</surname>
<given-names>H. J.</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Stephan</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Jentzmik</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma</article-title>. <source>Int. J. Cancer</source> <volume>126</volume> (<issue>5</issue>), <fpage>1166</fpage>&#x2013;<lpage>1176</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.24827</pub-id>
</citation>
</ref>
<ref id="B77">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schr&#xf6;der</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>E. D.</given-names>
</name>
<name>
<surname>Axcrona</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Payne</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Keane</surname>
<given-names>T. E.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Androgen deprivation therapy: past, present and future</article-title>. <source>BJU Int.</source> <volume>109</volume> (<issue>Suppl. 6</issue>), <fpage>1</fpage>&#x2013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1111/j.1464-410X.2012.11215.x</pub-id>
</citation>
</ref>
<ref id="B78">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>LncRNA PCAT1 activates AKT and NF-&#x3ba;B signaling in castration-resistant prostate cancer by regulating the PHLPP/FKBP51/IKK&#x3b1; complex</article-title>. <source>Nucleic Acids Res.</source> <volume>47</volume> (<issue>8</issue>), <fpage>4211</fpage>&#x2013;<lpage>4225</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkz108</pub-id>
</citation>
</ref>
<ref id="B79">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Chimeric RNAs in cancer</article-title>. <source>Adv. Clin. Chem.</source> <volume>100</volume>, <fpage>1</fpage>&#x2013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1016/bs.acc.2020.04.001</pub-id>
</citation>
</ref>
<ref id="B80">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Siegel</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Jemal</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Cancer statistics, 2014</article-title>. <source>CA Cancer J. Clin.</source> <volume>64</volume> (<issue>1</issue>), <fpage>9</fpage>&#x2013;<lpage>29</lpage>. <pub-id pub-id-type="doi">10.3322/caac.21208</pub-id>
</citation>
</ref>
<ref id="B81">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Siegel</surname>
<given-names>R. L.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>K. D.</given-names>
</name>
<name>
<surname>Jemal</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Cancer statistics, 2017</article-title>. <source>CA Cancer J. Clin.</source> <volume>67</volume> (<issue>1</issue>), <fpage>7</fpage>&#x2013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.3322/caac.21387</pub-id>
</citation>
</ref>
<ref id="B82">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Siegel</surname>
<given-names>R. L.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>K. D.</given-names>
</name>
<name>
<surname>Wagle</surname>
<given-names>N. S.</given-names>
</name>
<name>
<surname>Jemal</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Cancer statistics, 2023</article-title>. <source>CA Cancer J. Clin.</source> <volume>73</volume> (<issue>1</issue>), <fpage>17</fpage>&#x2013;<lpage>48</lpage>. <pub-id pub-id-type="doi">10.3322/caac.21763</pub-id>
</citation>
</ref>
<ref id="B83">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ramnarine</surname>
<given-names>V. R.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Pandey</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Padi</surname>
<given-names>S. K. R.</given-names>
</name>
<name>
<surname>Nouri</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer</article-title>. <source>Nat. Commun.</source> <volume>12</volume> (<issue>1</issue>), <fpage>7349</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-021-26901-9</pub-id>
</citation>
</ref>
<ref id="B84">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Slack</surname>
<given-names>F. J.</given-names>
</name>
<name>
<surname>Chinnaiyan</surname>
<given-names>A. M.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>The role of non-coding RNAs in oncology</article-title>. <source>Cell</source> <volume>179</volume> (<issue>5</issue>), <fpage>1033</fpage>&#x2013;<lpage>1055</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2019.10.017</pub-id>
</citation>
</ref>
<ref id="B85">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Souza</surname>
<given-names>M. F.</given-names>
</name>
<name>
<surname>Kuasne</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Barros-Filho</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Cili&#xe3;o</surname>
<given-names>H. L.</given-names>
</name>
<name>
<surname>Marchi</surname>
<given-names>F. A.</given-names>
</name>
<name>
<surname>Fuganti</surname>
<given-names>P. E.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Circulating mRNAs and miRNAs as candidate markers for the diagnosis and prognosis of prostate cancer</article-title>. <source>PLoS One</source> <volume>12</volume> (<issue>9</issue>), <fpage>e0184094</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0184094</pub-id>
</citation>
</ref>
<ref id="B86">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stafford</surname>
<given-names>M. Y. C.</given-names>
</name>
<name>
<surname>McKenna</surname>
<given-names>D. J.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>MiR-182 is upregulated in prostate cancer and contributes to tumor progression by targeting MITF</article-title>. <source>Int. J. Mol. Sci.</source> <volume>24</volume> (<issue>3</issue>), <fpage>1824</fpage>. <pub-id pub-id-type="doi">10.3390/ijms24031824</pub-id>
</citation>
</ref>
<ref id="B87">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stenman</surname>
<given-names>U. H.</given-names>
</name>
<name>
<surname>Leinonen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W. M.</given-names>
</name>
<name>
<surname>Finne</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>Prostate-specific antigen</article-title>. <source>Semin. Cancer Biol.</source> <volume>9</volume> (<issue>2</issue>), <fpage>83</fpage>&#x2013;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1006/scbi.1998.0086</pub-id>
</citation>
</ref>
<ref id="B88">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stoen</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Andersen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rakaee</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pedersen</surname>
<given-names>M. I.</given-names>
</name>
<name>
<surname>Ingebriktsen</surname>
<given-names>L. M.</given-names>
</name>
<name>
<surname>Bremnes</surname>
<given-names>R. M.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>High expression of miR-17-5p in tumor epithelium is a predictor for poor prognosis for prostate cancer patients</article-title>. <source>Sci. Rep.</source> <volume>11</volume> (<issue>1</issue>), <fpage>13864</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-021-93208-6</pub-id>
</citation>
</ref>
<ref id="B89">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sung</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ferlay</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Siegel</surname>
<given-names>R. L.</given-names>
</name>
<name>
<surname>Laversanne</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Soerjomataram</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Jemal</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>. <source>CA Cancer J. Clin.</source> <volume>71</volume> (<issue>3</issue>), <fpage>209</fpage>&#x2013;<lpage>249</lpage>. <pub-id pub-id-type="doi">10.3322/caac.21660</pub-id>
</citation>
</ref>
<ref id="B90">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Synnestvedt</surname>
<given-names>M. B.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Holmes</surname>
<given-names>J. H.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>CiteSpace II: visualization and knowledge discovery in bibliographic databases</article-title>. <source>AMIA Annu. Symp. Proc.</source> <volume>2005</volume>, <fpage>724</fpage>&#x2013;<lpage>728</lpage>.</citation>
</ref>
<ref id="B91">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szczyrba</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Nolte</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Wach</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kremmer</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>St&#xf6;hr</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hartmann</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Downregulation of Sec23A protein by miRNA-375 in prostate carcinoma</article-title>. <source>Mol. Cancer Res.</source> <volume>9</volume> (<issue>6</issue>), <fpage>791</fpage>&#x2013;<lpage>800</lpage>. <pub-id pub-id-type="doi">10.1158/1541-7786.Mcr-10-0573</pub-id>
</citation>
</ref>
<ref id="B92">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takahara</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ii</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Inamoto</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nakagawa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ibuki</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Yoshikawa</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>microRNA-145 mediates the inhibitory effect of adipose tissue-derived stromal cells on prostate cancer</article-title>. <source>Stem Cells Dev.</source> <volume>25</volume> (<issue>17</issue>), <fpage>1290</fpage>&#x2013;<lpage>1298</lpage>. <pub-id pub-id-type="doi">10.1089/scd.2016.0093</pub-id>
</citation>
</ref>
<ref id="B93">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tassone</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Di Martino</surname>
<given-names>M. T.</given-names>
</name>
<name>
<surname>Arbitrio</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fiorillo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Staropoli</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ciliberto</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study</article-title>. <source>J. Hematol. Oncol.</source> <volume>16</volume> (<issue>1</issue>), <fpage>68</fpage>. <pub-id pub-id-type="doi">10.1186/s13045-023-01468-8</pub-id>
</citation>
</ref>
<ref id="B94">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>T&#xe4;ubel</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hauke</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Rump</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Viereck</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Batkai</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Poetzsch</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study</article-title>. <source>Eur. Heart J.</source> <volume>42</volume> (<issue>2</issue>), <fpage>178</fpage>&#x2013;<lpage>188</lpage>. <pub-id pub-id-type="doi">10.1093/eurheartj/ehaa898</pub-id>
</citation>
</ref>
<ref id="B95">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taylor</surname>
<given-names>B. S.</given-names>
</name>
<name>
<surname>Schultz</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hieronymus</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Gopalan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Carver</surname>
<given-names>B. S.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>Integrative genomic profiling of human prostate cancer</article-title>. <source>Cancer Cell</source> <volume>18</volume> (<issue>1</issue>), <fpage>11</fpage>&#x2013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccr.2010.05.026</pub-id>
</citation>
</ref>
<ref id="B96">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Urabe</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Kosaka</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Sawa</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>miR-26a regulates extracellular vesicle secretion from prostate cancer cells via targeting SHC4, PFDN4, and CHORDC1</article-title>. <source>Sci. Adv.</source> <volume>6</volume> (<issue>18</issue>), <fpage>eaay3051</fpage>. <pub-id pub-id-type="doi">10.1126/sciadv.aay3051</pub-id>
</citation>
</ref>
<ref id="B97">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Niel</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>D&#x27;Angelo</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Raposo</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Shedding light on the cell biology of extracellular vesicles</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source> <volume>19</volume> (<issue>4</issue>), <fpage>213</fpage>&#x2013;<lpage>228</lpage>. <pub-id pub-id-type="doi">10.1038/nrm.2017.125</pub-id>
</citation>
</ref>
<ref id="B98">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Poppel</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Albreht</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Basu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Hogenhout</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Collen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Roobol</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future</article-title>. <source>Nat. Rev. Urol.</source> <volume>19</volume> (<issue>9</issue>), <fpage>562</fpage>&#x2013;<lpage>572</lpage>. <pub-id pub-id-type="doi">10.1038/s41585-022-00638-6</pub-id>
</citation>
</ref>
<ref id="B99">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Videira</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Beckedorff</surname>
<given-names>F. C.</given-names>
</name>
<name>
<surname>daSilva</surname>
<given-names>L. F.</given-names>
</name>
<name>
<surname>Verjovski-Almeida</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>PVT1 signals an androgen-dependent transcriptional repression program in prostate cancer cells and a set of the repressed genes predicts high-risk tumors</article-title>. <source>Cell Commun. Signal</source> <volume>19</volume> (<issue>1</issue>), <fpage>5</fpage>. <pub-id pub-id-type="doi">10.1186/s12964-020-00691-x</pub-id>
</citation>
</ref>
<ref id="B100">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vo</surname>
<given-names>J. N.</given-names>
</name>
<name>
<surname>Cieslik</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shukla</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>The landscape of circular RNA in cancer</article-title>. <source>Cell</source> <volume>176</volume> (<issue>4</issue>), <fpage>869</fpage>&#x2013;<lpage>881</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2018.12.021</pub-id>
</citation>
</ref>
<ref id="B101">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>MiR-182 promotes prostate cancer progression through activating Wnt/&#x3b2;-catenin signal pathway</article-title>. <source>Biomed. Pharmacother.</source> <volume>99</volume>, <fpage>334</fpage>&#x2013;<lpage>339</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2018.01.082</pub-id>
</citation>
</ref>
<ref id="B102">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>G. R.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>ncRNA-Encoded peptides or proteins and cancer</article-title>. <source>Mol. Ther.</source> <volume>27</volume> (<issue>10</issue>), <fpage>1718</fpage>&#x2013;<lpage>1725</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymthe.2019.09.001</pub-id>
</citation>
</ref>
<ref id="B103">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>P. L.</given-names>
</name>
<name>
<surname>Bao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yee</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Barrett</surname>
<given-names>S. P.</given-names>
</name>
<name>
<surname>Hogan</surname>
<given-names>G. J.</given-names>
</name>
<name>
<surname>Olsen</surname>
<given-names>M. N.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Circular RNA is expressed across the eukaryotic tree of life</article-title>. <source>PLoS One</source> <volume>9</volume> (<issue>6</issue>), <fpage>e90859</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0090859</pub-id>
</citation>
</ref>
<ref id="B104">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2024</year>). <article-title>A protein-encoding CCDC7 circular RNA inhibits the progression of prostate cancer by up-regulating FLRT3</article-title>. <source>NPJ Precis. Oncol.</source> <volume>8</volume> (<issue>1</issue>), <fpage>11</fpage>. <pub-id pub-id-type="doi">10.1038/s41698-024-00503-2</pub-id>
</citation>
</ref>
<ref id="B105">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lieberman</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1</article-title>. <source>Mol. Cancer</source> <volume>15</volume> (<issue>1</issue>), <fpage>70</fpage>. <pub-id pub-id-type="doi">10.1186/s12943-016-0556-9</pub-id>
</citation>
</ref>
<ref id="B106">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Long non-coding RNA NEAT1 promotes bone metastasis of prostate cancer through N6-methyladenosine</article-title>. <source>Mol. Cancer</source> <volume>19</volume> (<issue>1</issue>), <fpage>171</fpage>. <pub-id pub-id-type="doi">10.1186/s12943-020-01293-4</pub-id>
</citation>
</ref>
<ref id="B107">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>LncRNA MEG3 inhibits the progression of prostate cancer by modulating miR-9-5p/QKI-5 axis</article-title>. <source>J. Cell Mol. Med.</source> <volume>23</volume> (<issue>1</issue>), <fpage>29</fpage>&#x2013;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1111/jcmm.13658</pub-id>
</citation>
</ref>
<ref id="B108">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bian</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>MiR-203 down-regulates Rap1A and suppresses cell proliferation, adhesion and invasion in prostate cancer</article-title>. <source>J. Exp. Clin. Cancer Res.</source> <volume>34</volume> (<issue>1</issue>), <fpage>8</fpage>. <pub-id pub-id-type="doi">10.1186/s13046-015-0125-x</pub-id>
</citation>
</ref>
<ref id="B109">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z. M.</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>X. L.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Y. Z.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>CircSMARCC1 facilitates tumor progression by disrupting the crosstalk between prostate cancer cells and tumor-associated macrophages via miR-1322/CCL20/CCR6 signaling</article-title>. <source>Mol. Cancer</source> <volume>21</volume> (<issue>1</issue>), <fpage>173</fpage>. <pub-id pub-id-type="doi">10.1186/s12943-022-01630-9</pub-id>
</citation>
</ref>
<ref id="B110">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Tao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS</article-title>. <source>Mol. Cell Biochem.</source> <volume>350</volume> (<issue>1-2</issue>), <fpage>207</fpage>&#x2013;<lpage>213</lpage>. <pub-id pub-id-type="doi">10.1007/s11010-010-0700-6</pub-id>
</citation>
</ref>
<ref id="B111">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Long non-coding RNA PCAT-1 contributes to tumorigenesis by regulating FSCN1 via miR-145-5p in prostate cancer</article-title>. <source>Biomed. Pharmacother.</source> <volume>95</volume>, <fpage>1112</fpage>&#x2013;<lpage>1118</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2017.09.019</pub-id>
</citation>
</ref>
<ref id="B112">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>Y. H.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y. S.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Long non-coding RNAs in prostate cancer: functional roles and clinical implications</article-title>. <source>Cancer Lett.</source> <volume>464</volume>, <fpage>37</fpage>&#x2013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2019.08.010</pub-id>
</citation>
</ref>
<ref id="B113">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Long noncoding RNA GAS5 modulates &#x3b1;-Solanine-induced radiosensitivity by negatively regulating miR-18a in human prostate cancer cells</article-title>. <source>Biomed. Pharmacother.</source> <volume>112</volume>, <fpage>108656</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2019.108656</pub-id>
</citation>
</ref>
<ref id="B114">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>W. W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Khorshidi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rutnam</surname>
<given-names>Z. J.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Both mature miR-17-5p and passenger strand miR-17-3p target TIMP3 and induce prostate tumor growth and invasion</article-title>. <source>Nucleic Acids Res.</source> <volume>41</volume> (<issue>21</issue>), <fpage>9688</fpage>&#x2013;<lpage>9704</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkt680</pub-id>
</citation>
</ref>
<ref id="B115">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yao</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>M. K.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>The circSPON2/miR-331-3p axis regulates PRMT5, an epigenetic regulator of CAMK2N1 transcription and prostate cancer progression</article-title>. <source>Mol. Cancer</source> <volume>21</volume> (<issue>1</issue>), <fpage>119</fpage>. <pub-id pub-id-type="doi">10.1186/s12943-022-01598-6</pub-id>
</citation>
</ref>
<ref id="B116">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yao</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Butler</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression</article-title>. <source>Cell Death Dis.</source> <volume>11</volume> (<issue>8</issue>), <fpage>638</fpage>. <pub-id pub-id-type="doi">10.1038/s41419-020-02856-5</pub-id>
</citation>
</ref>
<ref id="B117">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yi</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lan</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>CircRNA and lncRNA-encoded peptide in diseases, an update review</article-title>. <source>Mol. Cancer</source> <volume>23</volume> (<issue>1</issue>), <fpage>214</fpage>. <pub-id pub-id-type="doi">10.1186/s12943-024-02131-7</pub-id>
</citation>
</ref>
<ref id="B118">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Weng</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Nano-vesicles are a potential tool to monitor therapeutic efficacy of carbon ion radiotherapy in prostate cancer</article-title>. <source>J. Biomed. Nanotechnol.</source> <volume>14</volume> (<issue>1</issue>), <fpage>168</fpage>&#x2013;<lpage>178</lpage>. <pub-id pub-id-type="doi">10.1166/jbn.2018.2503</pub-id>
</citation>
</ref>
<ref id="B119">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>lncRNA UCA1 functions as a ceRNA to promote prostate cancer progression via sponging miR143</article-title>. <source>Mol. Ther. Nucleic Acids</source> <volume>19</volume>, <fpage>751</fpage>&#x2013;<lpage>758</lpage>. <pub-id pub-id-type="doi">10.1016/j.omtn.2019.11.021</pub-id>
</citation>
</ref>
<ref id="B120">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2022a</year>). <article-title>CircCEMIP promotes anoikis-resistance by enhancing protective autophagy in prostate cancer cells</article-title>. <source>J. Exp. Clin. Cancer Res.</source> <volume>41</volume> (<issue>1</issue>), <fpage>188</fpage>. <pub-id pub-id-type="doi">10.1186/s13046-022-02381-7</pub-id>
</citation>
</ref>
<ref id="B121">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>Y. Z.</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>X. L.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2022b</year>). <article-title>Hsa_circ_0003258 promotes prostate cancer metastasis by complexing with IGF2BP3 and sponging miR-653-5p</article-title>. <source>Mol. Cancer</source> <volume>21</volume> (<issue>1</issue>), <fpage>12</fpage>. <pub-id pub-id-type="doi">10.1186/s12943-021-01480-x</pub-id>
</citation>
</ref>
<ref id="B122">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>J. C.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fong</surname>
<given-names>K. W.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y. A.</given-names>
</name>
<name>
<surname>Chakravarti</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>LncRNA HOTAIR enhances the androgen-receptor-mediated transcriptional program and drives castration-resistant prostate cancer</article-title>. <source>Cell Rep.</source> <volume>13</volume> (<issue>1</issue>), <fpage>209</fpage>&#x2013;<lpage>221</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2015.08.069</pub-id>
</citation>
</ref>
<ref id="B123">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chao</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>The short inverted repeats-induced circEXOC6B inhibits prostate cancer metastasis by enhancing the binding of RBMS1 and HuR</article-title>. <source>Mol. Ther.</source> <volume>31</volume> (<issue>6</issue>), <fpage>1705</fpage>&#x2013;<lpage>1721</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymthe.2022.08.006</pub-id>
</citation>
</ref>
<ref id="B124">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>AMPK/GSK3&#x3b2;/&#x3b2;-catenin cascade-triggered overexpression of CEMIP promotes migration and invasion in anoikis-resistant prostate cancer cells by enhancing metabolic reprogramming</article-title>. <source>Faseb J.</source> <volume>32</volume> (<issue>7</issue>), <fpage>3924</fpage>&#x2013;<lpage>3935</lpage>. <pub-id pub-id-type="doi">10.1096/fj.201701078R</pub-id>
</citation>
</ref>
<ref id="B125">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhong</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Knowledge mapping and current trends of immunotherapy for prostate cancer: a bibliometric study</article-title>. <source>Front. Immunol.</source> <volume>13</volume>, <fpage>1014981</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2022.1014981</pub-id>
</citation>
</ref>
<ref id="B126">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>X. D.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Min</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Advancement and properties of circular RNAs in prostate cancer: an emerging and compelling frontier for discovering</article-title>. <source>Int. J. Biol. Sci.</source> <volume>17</volume> (<issue>2</issue>), <fpage>651</fpage>&#x2013;<lpage>669</lpage>. <pub-id pub-id-type="doi">10.7150/ijbs.52266</pub-id>
</citation>
</ref>
<ref id="B127">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Mutations in GAS5 affect the transformation from benign prostate proliferation to aggressive prostate cancer by affecting the transcription efficiency of GAS5</article-title>. <source>J. Cell Physiol.</source> <volume>234</volume> (<issue>6</issue>), <fpage>8928</fpage>&#x2013;<lpage>8940</lpage>. <pub-id pub-id-type="doi">10.1002/jcp.27561</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>